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ABSTRACT 
A NOVEL POPULATION OF NATURAL KILLER CELLS PLAYS A CRITICAL ROLE IN 
THE DEPLETION OF SPLENIC B2 B CELLS DURING EXPERIMENTAL AFRICAN 
TRYPANOSOMIASIS 
 
FEBRUARY 2015 
 
DEBORAH RUTH FRENKEL, B.A., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Ph.D. UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Samuel J. Black 
 
Loss of humoral immune competence in T. brucei-infected mice is associated with the 
apoptotic depletion of splenic transitional, marginal zone and follicular B cells as well as a 
depletion of CD8+ T cells. This occurs rapidly after infection and impairs responses to vaccine 
antigens in addition to responses to newly arising VSG antigenic variants, leading to uncontrolled 
parasite growth and death of the infected mice.  Infection-induced B2 B cell and CD8+ T cell loss 
requires the presence of a novel population of natural killer (NK) cells and is mediated by a 
perforin-dependent process consistent with perforin- and granzyme-mediated cytotoxicity. The 
absence of perforin in deficient mice prevents infection-induced loss of splenic B cells, enhances 
trypanosome-specific antibody responses, reduces infection-associated anemia and prolongs 
survival after infection thus enhancing trypanosomiasis-resistance.   
Additionally, the parasite enzyme phospholipase C (PLC) is required for B2 B cell and Cd8+ T 
cell depletion.  Abrogation of infection induced immunopathology during infection with a PLC 
deficient parasite (PLC-/- T. brucei) is dependent on the presence of the antigen presenting 
molecule CD1d, as B2 B cell depletion and CD8+ T cell depletion occur during infection of 
CD1d-/- mice with PLC-/- T. brucei.  Natural killer cells acquire the same novel phenotype during 
infection with intact or PLC-/- T. brucei, however only during infection with the intact parasites 
are the NK cells shown to degranulate. 
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CHAPTER I  
GENERAL INTRODUCTION 
 
African Trypanosomiasis is a parasitic disease caused by protozoan parasites of the genus 
Trypanosoma (Fig. 1; for classification see Table 1.) which are transmitted to mammalian hosts 
by the bite of an infected tsetse fly (Glossina spp; Fig 2).  African Trypanosomiasis is endemic to 
the tsetse habitat, which encompasses an area approaching 10 million km2 and including 37 
countries[1].  There are about 30 species and subspecies of tsetse which are divided into 3 main 
groups known as the Morsitan group, the Palpalis group, and the Fusca group.  Tsetse species of 
the Morsitan group can be found in much of the savannah (grassy woodland) of Africa, whereas 
those of the Palpalis group are found in the mangrove swamps, the rain forest, the lake shores and 
the gallery forests along rivers, and those of the Fusca group are broken down into species which 
inhabit rather dry country, those that inhabit riverine valleys, and those that inhabit forested areas.  
Each species seems to be specialized to a particular climate condition [3,4,5].  Each species of 
Glossina has preferred host species on which it feeds but seems to be flexible if the presence of 
their preferred species is low or absent.  Within the tsetse habitat there is a notable absence of 
cattle (Fig 3 Cattle and Tsetse Distribution) purportedly due to trypanosomiasis which is often 
fatal in trypansomiasis-susceptible hosts including humans and livestock. There are several 
species of pathogenic African trypanosomes. Of these, two subspecies of Trypansoma brucei (T. 
b gambiense and T. b. rhodesiense) cause disease in humans (human African trypanosomiasis; 
HAT; respectively called west African HAT, and east African HAT) and a third sub species of T. 
brucei (T. b. brucei) together with T. vivax and T. congolense cause disease, called nagana, in 
livestock (animal African trypanosomiasis; AAT). 
2 
 
HAT epidemics have occurred periodically in Africa (Fig 4), one recently arising in the 
1970s. This was controlled by a rigorous regime of diagnosis and treatment implemented by the 
World Health Organization and sustained today[2]. Although the number of cases of HAT is 
currently maintained at relatively low levels, the same cannot be said for AAT, which is more 
prevalent and widely distributed than HAT. There are no straightforward, broadly applicable and 
affordable (for African countries) ways of controlling AAT, which therefore imposes substantial 
constraints to food sufficiency and socio-economic development of sub-Saharan Africa[6]. As 
indicated in Fig 3, the presence of tsetse and AAT precludes cattle based agriculture from vast 
areas of fertile land in the humid and semi-humid zones of sub-Saharan Africa.  Even where 
tsetse and trypanosome challenge is relatively low, i.e., on the fringes of the tsetse habitat where 
animal agriculture can be practiced only with support from chemotherapy and tsetse control, there 
is an estimated loss in cattle production alone at well over 1 billion U.S. dollars annually as a 
result of AAT.    
 
The parasites 
Trypanosoma brucei spp., has is the most extensively studied of the African trypanosomes. 
Trypansomes of T. brucei spp. are spindle shaped and measure about 20µm in length and 2µm in 
diameter at their widest point (Fig 1, 5).  Distinctive features of T. brucei include the large single 
mitochondria which spans the length of the cell, and the kinetoplast which is situated at the base 
of the flagellum and consists of circular (minicircles and maxicircles) mitochondrial DNA called 
kDNA (Figure 5) after which the Order Kinetoplastidae is named (Table 1 – classification).  
African trypanosomes including T. brucei have a single flagellum attached to the cell by an 
undulating membrane which allows motility. The flagellum originates within the flagellar pocket, 
an invagination of the parasite’s plasma membrane which serves as the endosomal gateway. 
Endocytosis, exocytosis and surface membrane turnover are all restricted to the trypanosome 
flagellar pocket [7].   T. brucei’s spindle shape and the unique way that the flagellum and 
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undulating membrane wraps around the parasite make it well adapted to motion in the crowded, 
viscous environment of its host blood plasma and interstitial fluids [8].  
T. brucei are digenetic parasites having life cycle stages in both mammalian hosts and 
their Glossina spp., vectors (Figure 5)[9,10].  In the mammalian blood stream, the 
trypanomastigote transitions from a long slender, dividing form to a short stumpy non-dividing 
form which is adapted to infect the tsetse fly vector.  Within the tsetse midgut, ingested 
bloodstream trypomastigotes transform into dividing procyclic forms which travel from the 
midgut to the proventriculus and further differentiate to the long epimastigote and then the short 
epimastigote. The parasite further migrates to the salivary gland where it differentiates into the 
non-dividing metacyclic (Figure 4).  It is the metacyclic form which is deposited into the 
mammalian host with the saliva of the tsetse fly beginning the cycle again. 
There are three sub-species of T. brucei, namely T. b. gambiense and T. b. rhodesiense 
which infect humans, and T. b. brucei which does not. The human infective T. brucei can survive 
in human serum during short term incubations, whereas T. b. brucei is rapidly lysed by human 
serum. This forms the basis of a simple diagnostic test. Lysis of T. b. brucei in human serum, 
which excludes the parasites from human infectivity, is mediated by 2 serum “trypanolytic 
factors” (TLF) called TLF1 and TLF2. Both contain haptoglobin related protein and ApoL1 
which contribute to their activity [11].  Uptake of the ApoL1 by T. b. brucei is most efficient 
when in complex with human haptoglobin, which binds specifically to the parasites. Within the T. 
b. brucei endosomal system Apolipoprotein L-1 forms ionic pores that destabilize lysosomes 
resulting in trypanosome autolysis.  Resistance of T. b. rhodesiense to ApoL1 is dependent on the 
expression of a serum resistance associated (SRA) gene which has been identified as a lysosomal 
protein [11,12] belonging to the VSG gene family [13].   Studies using transfection of SRA to T. 
b. brucei show that SRA binds ApoL1 preventing it being processed to form membrane 
destabilizing ionic pores thus conferring resistance to TLA [14]. T. b. gambiense is also resistant 
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to ApoL1 lytic activity although it does not express the SRA gene. Rather it uses several 
mechanisms to detoxify the ApoL1 [15]. 
The serum of baboons and other old world primates also has trypanolytic activity, which 
like that of human serum lyses T. congolense and T. vivax in addition to T. b. brucei 
[16,17,18,19].  Ongoing projects seeks to create transgenic cattle which express the human 
trypanosome lytic factor and baboon lytic factors and are thus engineered to resist infection with 
trypanosomes that cause Animal African Trypanosomiaisis[20].  While this project is promising 
and has the potential to open the door to agriculture in Tsetse endemic regions by generating 
trypanosomiasis-resistant cattle, no transgenic resistant cattle have yet been reported.  Moreover, 
the introduction of strains of livestock which express one or more human trypanolytic factors, 
possibly at sub-optimal levels, carries the risk of selecting for resistance to TLA in T. b. brucei 
and other species of African trypanosomes over time. 
VSG 
The primary adaptation of all African trypanosomes to life in the blood plasma is 
expression of a variable surface glycoprotein (VSG) coat. VSG is a glycophosphatidylinositol 
(GPI) anchored glycoprotein of about 65kD of which 107 copies are packed on the surface of the 
protozoan parasite as homodimers (Fig. 6)[9].   
Parasite phospholipase C (PLC) cleaves the GPI-anchor, releasing soluble VSG from the parasite 
surface.  In vitro this has been induced with different stressors including hypo-osmotic shock, 
acidic stress and calcium flux.  PLC is a virulence factor in T. brucei as PLC deficient T. b. brucei 
infected mice suffer less pathology and have significantly prolonged survival times as compared 
to animals infected with intact parasites[21,22]. The PLC-/- parasites retain their capacity to infect 
tsetse flies as well as mammals.  
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Parasites with an intact VSG coat poorly activate complement and hence are not subject 
to antibody-independent opsonization and phagocytosis, or antibody-independent complement 
mediated lysis[23,24]. In addition, antigenic variation of VSGs precludes rapid immune 
termination of infection. In this regard, the T. brucei genome has been shown to encode about 
1000 VSG genes and pseudogenes, the diversity of which is expanded by formation of mosaic 
VSG genes[2]. VSG gene expression is tightly regulated so that only a single VSG gene is 
expressed at a time. However the expressed VSG gene is varied stochastically resulting in a 
seemingly unlimited parade of new antigenic variants[2].  
 
Trypanosomiasis – The disease 
The earliest sign of infection in HAT and AAT is the appearance of a chancre, which is 
an indurated ulceration that arises at the site of infection between 5 to 15 days after tsetse bite. 
This is followed by a haemolymphatic stage in which the parasite escapes from the site of tsetse 
feeding and saliva deposition and invades the blood and tissues inducing immunopathology 
which results in lymphadenopathy, splenomegaly, hepatomegaly, cachexia and anemia[10,20]. 
During this stage the patient develops recurring fevers that coincide with waves of antigenically 
distinct parasites in the blood, and this is accompanied by enlargement of lymph nodes, joint pain, 
and facial edema. The infected hosts cannot clear infections with HAT and AAT parasite because 
these organisms are exemplars of antigenic variation as discussed above, stochastically changing 
variable surface glycoprotein (VSG) coats at low frequency which ensures a practically unlimited 
parade of new antigenic variants which evade on-going immune responses and maintain chronic 
infection.      
In the case of patients with HAT, the haemolymphatic stage occurs one to three weeks 
after the initial tsetse bite[25].  It lasts for only a few weeks in the case of infections with T. b. 
rhodesiense which are typically acute and characterized by high parasite loads in the blood 
6 
 
stream, and for several months in the case of infections with T. gambiense which is typically 
characterized by low levels of parasitemia and prolonged chronic or even asymptomatic infection. 
Over time human infective trypanosomes invade the central nervous system in many individuals 
causing the second stage of the disease, the neurological stage, which manifests as loss of co-
ordination, dizziness, headaches, confusion, dementia, disruptions of circadian rhythm, after 
which “sleeping sickness’ is named, and eventual coma and death[25].  
Animal African Trypanosomiasis, also called Nagana, is caused by a range of 
Trypanosome species including T.b.brucei, T.b gambiense, T. vivax, and T. congolense.  “Nagana 
is a wasting disease and manifests in initial waves of high parasitemia and fever. Infected cattle 
become “progressively thinner, their coat becomes rough and unkempt and the skin is drawn 
tightly over the ribs and pelvis lacking the looseness of healthy animals. There may be discharge 
from the eyes, visible swellings of the superficial lymph nodes and the tail bush may fall 
out”[26], all symptoms of systemic and peripheral inflammation.  These infected animals are 
unsuitable for meat, dairy, or draft [26,27,28].  The pathologic effects of trypanosomiasis on 
livestock not only reduces the availability of meat and dairy, but critically denies the use of cattle 
and horses for inedible fodder conversion to fertilizer, and for traction and transport.  Agricultural 
communities are then limited to what can be tilled by hand which leaves them vulnerable to food 
shortages, starvation, famine.  FAO (1994) estimated that for the whole of Africa, overall 
agricultural losses attributable to trypanosomiasis would total more than US$ 4 billion annually, a 
figure independently corroborated in 1999, when it was estimated that agricultural benefits 
accruing to tsetse elimination could reach US$ 4.5 billion per year[29]. 
 
Tsetse Control 
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The tsetse fly is a relative slow breeder with a female giving birth to just one offspring at 
a time and up to 8 during its lifespan[30].  Some scientists believe that this low rate of 
reproduction facilitates tsetse control and hence trypanosomiasis control at least in restricted 
regions as a means of reducing infection incidence [31,32,33].  Tsetse Chemoattractants have 
been identified and a variety of traps developed that can be used to deplete tsetse from 
agricultural areas if widely distributed and rigorously maintained (Fig. 7).    
However, this approach is limited by lack of resources and of central organization.[3,34].  
When traps and targets are effective it is a challenge to maintain local interest in maintaining the 
trap as the idea that tsetse are a threat wanes with lowered incidence of infection of humans and 
livestock leading to potential reemergence[35].  Tsetse can also be controlled by spraying of 
insecticides, and ambitious programs have been proposed to clear large areas of infested land in 
this manner.  However, insecticide spraying is expensive and would have to deplete tsetse from 
the entirety of Africa to have a lasting effect because the tabanids can re-infest cleared 
areas[6,32,33].  Currently local insecticide application, in the form of underbelly spraying is used 
to protect individual animals but is a practice reserved for valuable animals and used by relatively 
wealthy farmers. Widespread release of sterile male tsetse, which compete with fertile males for 
mates, has also been explored as a general control measure, but is very expensive and at best a 
temporary measure[33,36]. Overall, the large number of tsetse species, their wide distribution, 
reduced application of control measures during times of political unrest and  low funding, reduces 
the efficacy of tsetse control (along with all efforts to control disease instance) as a means of 
controlling trypanosomiasis [37].  Although large scale efficacy of tsetse control is debatable, 
many still believe this to be an integral limb of the multifaceted effort to controlTrypanosomiasis 
and efforts to control the vector and disease continue.  As an example, case numbers in the 
Democratic Republic of Congo are shown in Figure 4. 
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Chemotherapy / Drug Resistance 
The drugs used to treat Trypanosomiasis were introduced before 1950 with very few 
innovations in drug development since[38].  For over 50 years there have been just a small 
number of primary drugs on the market to control Animal African Trypanosomiasis (AAT).  
These drugs are Homidium salts in the form of Homidium-chloride (Novidium) or Homidium-
bromide (Ethidium), Diminazine acerurate (Berenil), Isometamidium chloride (Samorin, 
Trypanidium), and more recently Quinapyramine sulphate, which has been used to combat 
trypanosomiasis in camels[38,39].  Treatment of individual infected animals is still the most 
common method of control used by farmers with an estimated 30,000 thousand therapeutic doses 
being purchased per year, which is estimated to be only one tenth the number of doses needed 
given the number of animals at risk of infection.   
 Use of chemotherapy is moderately effective in a few scenarios [39], for example, in the 
case of ranchers moving cattle temporarily into tsetse habitat in order to take seasonal advantage 
of grazing land and available water or while driving cattle through tsetse infested areas.  
Chemotherapy is also a helpful tool for minimizing losses in the event of a sporadic outbreak of 
Trypanosomiasis in a region which does not experience much trypanosomiasis[40] or, when used 
in combination with traps or screens, chemotherapy can make cattle raising feasible in areas of 
low tsetse prevalence.   
However, in tsetse endemic areas it is not feasible to control AAT with 
chemotherapy[39].  Treatment of an animal or herd does not preclude reinfection meaning that in 
endemic areas animals would require regular treatment with trypanocidal drugs.  The cost of 
repeated treatments is prohibitive to most farmers.  Moreover, when trypanocidal drugs are used 
over time, drug resistance begins to emerge and has been documented in several countries 
[41,42,43].  In addition, administration of trypanocidal drugs to livestock is typically carried out 
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without veterinary oversight and under-dosing is common in order to save money and leads to 
uncured animals and raised risk of emergence of drug resistant Trypanosome species.   
Similar issues prevail in the treatment of Human African Trypanosomiasis (HAT) in that 
there are limited options for chemotherapy, most of which are antiquated and resistance has 
begun to emerge.  HAT must be treated differently depending on whether the disease has 
progressed to late meningo-encephalitic stage in which the parasites have invaded the central 
nervous system (CNS).  Early or haemo-lymphatic stage HAT is treated with one of 3 drugs, 
pentamidine, suramin, and berenil which, because of its effectiveness is widely used by 
physicians despite it being licensed only for veterinary use.  Late stage disease is more difficult to 
treat as drugs must cross the blood-brain barrier.  Melarsoprol has been the mainstay for treating 
late stage trypanosomisais but has a high rate of toxicity which manifests in arsenical-induced 
encephalopathy followed by pulmonary edema and death.  More recently, eflornithine has entered 
the market for treating late stage HAT.  Some of the issues clinics are confronted with are the 
extended and complex nature of the treatment regime for both early and late stage disease[25].  
Treatment is carried out via intravenous or intramuscular injection over many days to weeks.  For 
instance eflornithine, which has lower incidence of side effects than melarsoprol, requires four 
daily injections for 7 to 14 days.  This poses both financial as well as practical challenges in 
treating HAT.  As with treatment of AAT, HAT is running up against treatment failures which are 
likely the result of drug resistance.  With a limited number of drugs available for the treatment of 
HAT, all of which have been on the market for up to and over 50 years, emergence of drug 
resistance would lead to a resurgence of  HAT. 
 
Vaccination 
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No efficacious vaccine has been developed against any of the African trypanosomes and 
it is a widely held view that vaccines capable of inducing sterile immunity cannot be developed 
against these parasites because of antigenic variation of the VSG coat. This view is supported by 
studies showing that the VSG coat masks conserved plasma membrane antigens with the 
exception of receptors for macromolecular nutrients, which do not serve as vaccine antigens. As 
mentioned above, the surface of a trypanosome is covered with a 10 million copies of a variant 
surface glycoprotein (VSG) arranged in a contiguous array of homodimers.  Expression of surface 
VSG is under constant low level stochastic change.  The volume and arrangement of VSG 
homodimers on the cell surface does not allow for interaction with antibody molecules with 
underlying invariant parasite surface molecules.  Inoculation with and subsequent antibody 
production against receptors for macromolecule nutrient uptake which protrude out from the VSG 
coat in the flagellar pocket have proven ineffective at offering protection[44].  Antibodies against 
these receptors are outcompeted by nutrient ligand and, once bound by ligand, receptors are 
internalized and therefore antibodies fail to opsonize the parasite for phagocytosis or compliment 
mediated lysis.  Because of the vast potential for variation in surface glycoprotein and lack of 
protection offered from antibodies against flagellar pocked exposed receptors it is widely 
believed that it is unlikely that effective vaccine against T.brucei will be developed. 
AAT and HAT have proven difficult to control with chemotherapy alone and even 
combined with vector control measures success is limited and quickly reversed when the efforts 
of aid agencies are interrupted for any length of time[38,39,45].  Currently utilized 
chemotherapeutics are old, treatment regimens and toxicity are major obstacles, drug resistance is 
an emerging problem in both HAT and AAT, and an effective vaccine has proven elusive.  We 
are left with a vacuum in the place of effective treatment and control of a disease which reigns 
over a large region of the African continent.  Deeper insight into the immunological interface 
between parasite and host has the potential to lead the field to new targets and tools leading to 
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effective disease control and prevention.  Though there is little hope for a vaccine that can 
prevent infection with African trypanosomes, there remains hope that anti-pathology vaccines can 
be developed, particularly a vaccine that prevents infection-associated depression of humoral 
immunity and improves VSG-specific primary and secondary immune responses at all stages of 
infection thus allowing infected hosts to better control trypanosome parasitemia and eventually 
self-cure. 
 
Immunosupression 
During infection there is general disruption of lymphoid tissue structure; 
trypanosusceptible species develop splenomegaly, hepatomegaly, hypergammaglobulinemia, 
anemia and weight loss [46,47,48,49,50].  Paradoxically, hypergammaglobulinemia is 
accompanied by progressive immunodeficiency as parasite specific IgM and IgG responses 
decline along with the decline of a recall response to vaccine antigen as infection progresses [51]. 
Although immunosuppression is a common characteristic of trypanosomiasis in all susceptible 
host species, this is not the case with trypanosomiasis resistant host species [52,53].   
Understanding the mechanisms behind immune suppression, in particular loss of the humoral 
immune response may pave the way to developing effective vaccine strategies for control of 
disease and disease pathology associated with African Trypanosomiasis.  If the humoral response 
can be spared or restored during infection there is hope for increased resistance to 
trypanosomiasis, i.e., sustained control of parasitemia, reduced anemia and prolonged survival. 
 
Trypanopsomiasis resistance and susceptibility  
Some animals e.g., Cape buffalo and Eland, which co-evolved with tsetse and African 
trypanosomes, rapidly suppress levels of parasites to a minimal (cryptic) level and show no signs 
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of disease[52,53]. Similarly some breeds of cattle, including the West Africa Ndama are less 
affected by AAT than others and can be maintained under levels of tsetse and trypanosome 
challenge that rapidly lead to death of other breeds [54].    Analyses of disease resistance 
mechanisms in these animals have so far proven unrewarding.  Long term control of trypanosome 
parasitemia in Cape buffalo is associated with the very efficient development of IgG antibody 
responses against newly arising trypanosome variable surface protein (VSG) types, but not with 
the development of antibodies against common protective antigens[52,53].  In addition, to 
suppressing parasitemia to a cryptic level, infected Cape buffalo do not develop anemia or other 
signs of disease.  Similarly, infected Ndama develop lower levels of parasitemia and less severe 
anemia than similarly infected trypansosomiasis-susceptible Boran cattle, and mount stronger 
primary and recall IgG responses against trypanosome antigens that Borans [55,56]. Strains of 
mice have also been shown to differ in their capacity to control infections with T. brucei and T. 
congolense with the more resistant strains developing lower levels of parasitemia, surviving for a 
longer period and mounting stronger VSG specific antibody responses than the more 
trypansomiasis-susceptible mice[57,58,59,60]. 
  Immune responses of infected mice to African trypanosomes are not restricted to 
production of VSG-specific and other antibodies. T cells are also induced to respond and their 
responses have been shown to contribute to control of infection [61,62]. Both mouse and human 
response to trypanosome infection include production of interferon γ (INF-γ), tumor necrosis 
factor alpha (TNF-α), interleukin 4 (IL-4), interleukin 6 (Il-6), interleukin 10 (Il-10), and 
transforming growth factor beta (TGF-β)[61,63,64].[61,63,64].   Interferon gamma is thought to 
contribute to control of trypanosomes in tissues by stimulating macrophages to produce H2O2 and 
NO which are potent trypanocides, and to contribute to control of trypanosomes in the blood by 
stimulating IgG1 responses. However, the cytokine also has strong pro-inflammatory activity and 
sustained production is debilitating for the host. Thus longer survival is associated with an early 
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TH1-like response with production of INF- γ which transitions to a TH2 like response later in 
infection characterized by increased expression of the counter-inflammatory cytokine IL-10, 
whereas sustained production of INF-γ leads to early death[21,65,66].  
The mechanism through which T. brucei regulates Th1 and Th2 responses is not 
resolved. However, deletion of the T. brucei gene encoding GPI-PLC reduces its virulence[22], 
facilitates in the host a switch from a pro-inflammatory TH1 to an anti-inflammatory TH2 T cell 
response during infection[57,67], and reduces the degree of immunosuppression and pathology 
induced by the parasites[21]. It is therefore possible that soluble VSG, which is released from T. 
brucei upon cleavage of GPI by GPI-PLC, or remnant GPI play a role in stimulating the potent 
inflammatory response to the parasites. This is consistent with in vitro studies showing that. 
Responses of inflammatory macrophages and TNF-producing/iNOS-expressing dendritic cells are 
induced by trypanosome components, particularly the GPI-PLC-cleavage fragments of the 
membrane form of VSG[61,68].  Inflammatory macrophages and TNF-producing/iNOS-
expressing dendritic cells (tipDC) are implicated in mechanisms of T. brucei-induced 
immunosuppression and immunopathology[69,70,71,72,73,74], although it is unclear how they 
down regulate VSG specific IgG antibody responses, and indeed humoral immunity in general, 
which is a key feature of  trypanosomiasis-susceptibility in infected cattle as well as in infected 
mice. 
 
Focus of this thesis    
We have recently shown in collaboration Stefan Magez that loss of humoral immune 
competence in T. brucei-infected mice is associated with the apoptotic depletion of splenic 
transitional, marginal zone and follicular B cells[75]. This occurs rapidly after infection and 
impairs responses to vaccine antigens in addition to responses to newly arising VSG antigenic 
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variants, leading to uncontrolled parasite growth and death of the infected mice[76]. B cell loss 
has also been shown to occur in mice infected with the S. American trypanosome T. cruzi , where 
it is associated with a Fas-L dependent fratricidal reaction and with production of 
prostaglandins[77,78,79] . However, this does not appear to be the mechanism of B cell depletion 
in murine African trypanosomiais, which occurs to a similar degree in lpr, i.e., Faslo mice[75], in 
mice administered antibodies against Fas-ligand and in mice treated with indomethacin to prevent 
cyclooxygenase activity and production of prostaglandins. In addition T. brucei–induced B cell 
loss does not require host production of TNFα showing that it is independent of TNF dependent 
death pathways[75]. 
In this thesis I have attempted to elucidate the mechanism of T. brucei-infection induced 
B cell apoptosis using mice lacking various aspects of the immune system as a result of gene 
deletion or antibody administration. In addition, I have examined the role of T. brucei GPI-PLC 
in this process and whether cells in addition to splenic B cells are affected. I consider that 
understanding the mechanism of T. brucei infection-induced B cell deletion in the infected mice 
will contribute to a fundamental understanding of infection-associated immunopathology, will 
stimulate similar investigations in livestock species and has the potential to lead to a greater 
understanding of the mechanism of trypanosomiasis susceptibility in general.  
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Figure 1.1  Gimsa stain of T. brucei in bloodstream of 
mammalian host.  - Parasitology Images: An Auto-tutorial  Thomas P. 
Buckelew, Ph.D. 
 
16 
 
Figure 1.2 Photos of Glossina (a) before and (b) after blood meal used with permission from Dr. Ray Wilson. 
 
a b
 
  
Figure 1.3 Distribution of Tsetse.  Grey shading denotes tsetse endemic areas. 
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Figure 1.4  Number of cased of HAT in the Democratic Republic of Congo by year[2]. 
 
Figure 1.5 Trypanosoma brucei life cycle and anatomy. 
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Fig 1.6 Graphic representation of GPI anchored  VSG homodimer 
Figure 1.7 Tsetse trap and April 1931 catch 
19 
 
CHAPTER II 
NKP46-VE NATURAL KILLER CELLS DELETE B2 B CELLS AND SUPPRESS 
HUMORAL IMMUNITY IN MURINE AFRICAN TRYPANOSOMIASIS 
 
Abstract 
Infection with Trypanosoma brucei results in recurring waves of parasitemia and often 
fatal disease in humans and livestock. Clearance of the highly antigenically variable 
extracellular parasites from the bloodstream is mediated by antibodies specific for their 
variable surface glycoproteins (VSG). However, these responses, particularly VSG 
specific IgG responses, are suppressed in trypanosomiasis-susceptible hosts. In previous 
studies, using the T. brucei AnTat 1.1E C57BL/6 mouse model, we have shown that 
suppression of VSG-specific antibody responses results from severe depletion of splenic 
transitional, marginal zone and follicular B cells. We now show that this process is 
mediated by a novel subpopulation of natural killer (NK) cells as follows: T. brucei 
infection-induced B cell deletion was similar in intact and T cell deficient mice excluding 
involvement of T cells and NKT cells, but did not occur in mice depleted of NK1.1+ 
lymphocytes by mAb PK136 indicating the involvement of NK cells. These NK cells did 
not express the NKp46 activating receptor or CD49b the integrin α2 subunit of the 
collagen receptor, distinguishing them from mature NK cells and tumor-destructive NK 
cells. Although the NK cells expressed both high levels of the death ligand FasL and the 
cytotoxic granule marker CD107a, B cell deletion was primarily perforin-dependent and 
hence a result of cell mediated cytotoxicity. Perforin-/- mice retained splenic B2 B cells 
and B cell follicles throughout infection and developed high titer IgG responses against 
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many trypanosome polypeptides unlike similarly infected intact mice. In addition, they 
had a lower level of parasitemia, did not develop anemia and had prolonged survival 
compared to similarly-infected intact mice. We conclude that a population of NKp46- NK 
cells in T. brucei infected mice kills trypanosome antigen-specific and other B2 B cells 
and inactivation of their cytotoxic function improves control of parasitemia and decreases 
pathology thus increasing trypanosomiasis-resistance.  
 
 Author Summary 
African trypanosomiasis caused by Trypanosoma brucei species is fatal in 
humans and trypanosomiasis-susceptible animals and cannot be combated by vaccination 
because of extensive parasite antigenic variation. Effective trypanosome control and 
clearance from the bloodstream involves the action of antibodies specific for the 
parasite’s highly diverse variable surface glycoprotein antigens. However, experimental 
T. brucei infection in mice depletes splenic B cells which results in a loss of protective 
anti-trypanosome antibodies. Here, we show that infection-induced B cell loss requires 
the presence of a novel population of natural killer (NK) cells and is mediated by a 
perforin-dependent process consistent with perforin- and granzyme-mediated 
cytotoxicity. The absence of perforin in deficient mice prevents infection-induced loss of 
splenic B cells, enhances trypanosome-specific antibody responses, reduces infection-
associated anemia and prolongs survival after infection thus enhancing trypanosomiasis-
resistance. 
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Introduction 
 
Trypanosoma brucei spp., are highly antigenically variable protozoan parasites 
that inhabit the blood plasma and tissue fluids of their mammal hosts. The tsetse-
transmitted parasites are endemic throughout the tsetse habitat which encompasses a land 
mass of approximately ten million square kilometers of the humid and semi-humid 
regions of sub-Saharan Africa. Two subspecies of T. brucei, namely T. b. gambiense and 
T. b. rhodesiense cause Human African Trypanosomiasis (HAT;) and a third subspecies, 
T. b. brucei, together with T. congolense and T. vivax, which belong to the same suborder 
but different subgenera to T. brucei, cause Animal African Trypanosomiasis (AAT). 
HAT and AAT are characterized by recurring wave of parasitemia in which new 
antigenic variants evade prior and ongoing immune responses and boost 
immunopathology often killing the host.  
HAT threatens 60 million people and is controlled by a rigorous and sustained 
regime of diagnosis and treatment. AAT excludes cattle from vast tracts of the tsetse 
habitat. Where ranching of trypanosomiais-susceptible livestock is possible, it is 
supported by chemotherapy and anti-vector strategies with an estimated AAT-associated 
production loss of about four billion US dollars per year [80]. Research on sustainable 
control of AAT has focused both on prevention of infection and alleviation of disease in 
infected animals. Approaches include development of a broad-acting anti-infection 
vaccine, which has so far proven unsuccessful [81], prophylactic anti-parasite 
transgenesis which is ongoing [82], targeted inhibition of parasite enzymes that cause 
pathology, which has yet to be achieved [83], and prevention of trypansomiasis-
22 
 
associated immunosuppression, which we show here using a mouse model of AAT 
increases host resistance to trypanosomiasis. 
Immunosuppression is a universal but poorly understood feature of African 
trypanosomiasis in susceptible hosts [84,85].  Studies in vitro [86] and in vivo [87] 
implicate nitric oxide (NO) produced by macrophages and dendritic cells in impaired 
proliferative responses of leukocytes in mouse models of trypanosomiasis consistent with 
a role in infection-induced immunosuppression. However, studies in cattle with AAT 
suggest that NO is not responsible for reduced leukocyte proliferation [88]. Similarly, 
studies in T. brucei-infected mice show that prostaglandin E2 production parallels 
development of immunosuppression [89]. However, ablation of its production by 
indomethacin treatment did not prevent the development of immunosuppression in the 
mice [75] and did not restore mitogen-induced proliferative responses of T cells from 
cattle with AAT [90]. B cell clonal exhaustion has also been proposed as the cause of 
immunosuppression [49], consistent with the development of lymphopenia in cattle and 
sheep with AAT [91,92,93] and with ablation of bone marrow lymphopoiesis and 
deletion of splenic transitional, marginal zone (MZ) cells and follicular (Fo) B cells in 
mice infected with T. brucei [75,94].  The loss of these B cells, which are from the B2 
lineage [95,96], severely compromises trypanosome specific antibody production [76], 
and occurs after infection with any of several different isolates of T. brucei (Black 
Laboratory, unpublished data) as well as with a T. congolense isolate [97]. Splenic B cell 
deletion also occurs in mice infected with T. vivax [98] although this has not been 
specifically typed to the B2 lineage.   
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In contrast to splenic B2 B cells, which are depleted from the spleens of T. brucei 
infected mice, the number of IgM+CD5lowCD11b+ splenic B cells increases significantly 
(supplementary Figure 1). The origin of these B cells has not been established but their 
phenotype suggests they are related to B1a-derived B cells (IgM+CD5+CD11b+) [99] and 
B1b B cells (IgM+CD5-CD11b+) [100]. Splenic B1 B cells also increase in number in 
infected trypanosomiasis-susceptible cattle [101] which, in common with T. brucei-
infected mice, mount poor trypanosome antigen-specific IgG responses indicating poor 
stimulation of T cell dependent antibody responses [85]. Although B cell dynamics have 
not been studied in patients with T. b. rhodesiense HAT, which is an acute disease, 
analysis of peripheral blood B cells has been performed in patients with T. b. gambiense 
HAT, which is a chronic disease. In these patients there is a significant increase in T cell-
independent B cells and a significant decrease in T cell-dependent B cells as a percentage 
of total blood lymphocytes [102] accompanied by a significant, although non-threatening, 
decrease in anti-measles antibody in serum, relative to age, gender and habitat matched 
uninfected individuals. The infection-induced mechanism(s) that cause the deletion of 
splenic B2 B cells in trypanosome infected mice, and those that prevent the development 
of trypanosome-specific IgG antibodies in infected cattle and cause the proportional 
decrease in T cell dependent relative to T cell independent B cells in the peripheral blood 
of T. b. gambiense infected people have not been identified. 
 Here we used gene knock-out mouse strains and antibody-mediated deletion of 
putative effector cells to show that B2 B cells are deleted from the spleens of infected 
mice by T cell-independent but natural killer (NK) cell-dependent processes. Importantly, 
we show that splenic B2 B cells are not deleted in T. brucei-infected mice that lack the 
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gene encoding perforin (perf-/-) which therefore have a greatly increased capacity to 
mount trypanosome antigen specific antibody responses, especially those of the IgG 
class, compared to similarly-infected intact mice. In addition the infected perf-/- mice 
controlled parasitemia, maintained their body weight and blood packed cell volume and 
survived for up to 90 days after infection, whereas similarly infected intact mice lost the 
capacity to control parasitemia, developed severe anemia and died by 30 to 35 days after 
infection. The studies identify NK cell mediated cytotoxicity as the mechanism of 
trypanosome infection-induced B2 B cell deletion in infected mice and show that 
abrogation of this process increases the resistance of the infected mice to AAT. 
 
Results 
Retention of splenic B2 B cells and production of trypanosome antigen-specific IgG 
in T. brucei-infected perf-/-mice 
 Perforin is a pore forming protein found in cytotoxic granules of cytotoxic T 
cells, NKT cells and NK cells. The protein works together with granzymes, which are 
serine proteases found in the same granules, to kill cells on which they are deposited 
[103]. To determine the contribution of perforin to T. brucei infection induced B cell 
killing, intact and perf-/- mice were infected with T. brucei Antat 1.1E and the percentage 
and number of transitional, MZ and Fo B cells as determined by staining with antibodies 
listed in Table 1 determined at intervals thereafter.  Although mice of both strains 
developed similar levels of first wave parasitemia (Fig.1A vs Fig 2A), perf-/- mice, for the 
most part, maintained splenic transitional type 1, type 2, and type 3 B cell populations 
(Fig. 1B-D, H, I) as well as splenic MZ and Fo B cell populations , (Fig. 1E, F, J, K) at, 
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or greater than, pre-infection levels throughout infection whereas these cell populations 
were depleted from the spleens of infected intact mice (Fig 2B-F, H-K). Our results 
indicate that T. brucei-induced splenic B cell depletion is perforin-dependent and thus is 
most likely caused by cytotoxic cells, the only cells to express perforin.  
 
Not only were splenic transitional, MZ and Fo B cell populations maintained in 
the spleens of perf-/- mice infected with T. brucei AnTat 1.1E, the mice did not develop 
anemia evidenced by maintained blood packed cell volume (Fig 1G). In contrast, blood 
packed cell volume declined significantly in infected intact mice (Fig 2G).  
B cell follicles, identified in cross sections of spleen as a large cluster of B220+ B 
cells with a rim of MOMA+ marginal zone macrophages, were numerous and similar in 
distribution in uninfected C57BL/6 mice and perf-/- C57BL/6 mice (Fig 3A, B). However, 
the follicles were greatly reduced in distribution (not shown) and size in the spleens of 
C57BL/6 mice 10 days post infection (dpi) and those remaining had substantially 
decreased presence of MOMA+ cells (Fig 3C). B cell follicles were completely absent 
from the spleens of C57BL/6 mice at 30 dpi (Fig 3E), but remained prevalent in the 
spleens of perf-/- C57BL/6 mice at 10 and 30 dpi (not shown). However, despite retaining 
large numbers of B220+ cells B cells, follicles in infected perf-/- mice also showed 
decreased presence and staining intensity of MOMA+ cells (Fig 3D,F) which requires 
further investigation. Importantly, T. brucei infected perf-/- mice developed and sustained 
robust trypanosome antigen specific IgM and IgG responses while those of similarly 
infected intact mice were of lower titer and shorter duration (Fig. 4A,C). Moreover 
infected intact mice generated IgM and IgG antibodies against only a few trypanosome 
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polypeptides by day 30 after infection, whereas infected perf-/- mice generated antibodies 
against a large number of trypanosome polypeptides (Fig. 4B,D).  
T cells and NKT cells are not required for T. brucei infection-induced B cell deletion   
CD8+ cytotoxic T cells kill target cells via the perforin/granzyme pathway, as do 
NKT cells and NK cells [103,104,105,106] .  Mice that lack the genes encoding the T cell 
receptor beta and delta chains (TCR-/-) and consequently αβ and γδ T cells as well as 
Natural Killer T (NKT) cells were used to determine the impact of these cells types in T. 
brucei infection induced B cell deletion. The numbers of transitional, MZ and Fo B cells  
were significantly decreased in TCR-/- mice infected for 10 days with T. brucei AnTat 
1.1E compared to naïve TCR-/- mice (Fig. 5A-E) and the extent of splenic B cell deletion 
was similar to that in intact mice infected with the parasites (Fig 2B-F, H-K).   Therefore, 
T cells are neither directly nor indirectly responsible for perforin-dependent deletion of 
splenic B cells in the infected mice.   
 
NK cells are required for T. brucei infection-induced B cell deletion  
NK cells (CD3- NK1.1+) can be eliminated from mice through treatment with 
monoclonal antibody against the NK1.1 differentiation antigen, which also depletes NKT 
cells (CD3+ NK1.1+) [107,108,109,110]. The intraperitoneal administration of NK1.1 
specific monoclonal IgG2a antibody to C57BL/6 mice resulted in almost complete loss of 
NK1.1+ spleen cells within 4 days (not shown) and NK1.1+ cell depletion was maintained 
for 10 days by subsequent NK1.1-specific antibody administration on days 4, and 7 after 
the initial treatment (Data for day 10 anti-NK1.1 shown in Fig. 6A top panel). In contrast, 
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administration of an irrelevant IgG2a monoclonal antibody to intact C57BL/6 mice under 
the same regime did not affect splenic NK1.1+ cells (Fig 6A, bottom panel). Neither the 
anti-NK1.1 nor the irrelevant IgG2a monoclonal antibody affected the number of 
transitional, MZ or Fo B cells in the spleen (not shown). However, depletion of NK1.1+ 
cells by antibody administration to T. brucei AnTat 1.1E-infected mice on days -1, 3 and 
7 after infection prevented, with the exception of transitional type 2 B cells, depletion of 
splenic B cells, whereas similar administration of control antibody did not prevent B cell 
depletion (Fig 6B-F). In 4 repeat experiments, treatment with the anti-NK1.1 mAb 
always prevented infection-induced elimination of T3, MZ and FoB cells, and in 2 of 
these studies also prevented infection-induced elimination of T2 B cells (data not shown). 
These data show that NK1.1+ cells are required for T. brucei infection-induced depletion 
of splenic T3, MZ and Fo B cells and taken together with results obtained in perf-/- mice 
(Fig 1) and TCR-/- mice (Fig 5) indicate that NK cells are responsible for the perforin-
dependent, T cell-independent loss of splenic B cells from the infected mice.   
   
 
NK cells in T. brucei infected mice have a novel phenotype  
  Most splenic NK cells in naïve mice expressed the natural cytotoxicity receptor 
NKp46 (Fig 7A) and the integrin alpha subunit CD49b (Fig 7B). They also expressed 
little to no FasL (Fig 7C) or TRAIL (Fig 7D), which are ligands for the death receptors 
Fas and DR5 respectively, and expressed little or no lysosomal-associated membrane 
protein 1 (LAMP-1 also called CD107a) on their surface (Fig. 7E) as expected for resting 
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cells.  Most splenic NK cells at 7 days after infection, which is the time of remission of 
the first parasitemic wave (Fig 2A), had the same phenotype as those present in naïve 
mice (data not shown), however by 10 days post infection, by which time viable splenic 
B cells are predominantly deleted,  expression of NKp46 and CD49b by splenic NK cells 
was greatly decreased in comparison to NK cells in naïve and day 7 infected mice (Fig 
7A,B), and that of FasL, and CD107a was greatly increased (Fig 7C,E), while expression 
of TRAIL was only slightly increased (Fig 7D).  
 
CD107a facilitates delivery of perforin to the cytotoxic granules of NK cells 
[111,112,113,114] and is placed on the surface of the cells upon their degranulation 
which occurs during target-cell killing.  Thus, the increased expression of CD107a on the 
surface of infection-activated NK cells (Fig. 7E), together with the perforin-dependence 
of B cell deletion from the spleens of infected mice (Fig 1) support the view that 
infection-activated NK cells delete B cells by perforin and granzyme-dependent 
cytotoxicity.  Never-the-less, because infection-activated NK cells also express high 
levels of FasL (Fig 7C) and slightly increased levels of TRAIIL (Fig 7D), it is also 
possible that perforin- and granzyme-dependent killing is amplified by death receptor 
signaling. To address this possibility, the expression of Fas and DR5 (respectively death 
receptors for FasL and TRAIL) was determined on membrane impermeable (7AAD-; 
healthy) versus membrane permeable (7AAD+; dieing/dead) IgM+ B cells in mice that 
had been infected 10 days earlier with T. brucei AnTat 1.1E. The study showed that Fas 
expression was similar on IgM+ cells of naïve and infected mice irrespective of whether 
or not they took up 7AAD (Figs 8A,B). In addition, although DR5 expression was 
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slightly increased on 7AAD+ compared to 7AAD- IgM+ cells of naïve mice (Fig 8D and 
8C), this difference was not observed in 7AAD+ and 7AAD- IgM+ cells of infected mice. 
Thus cells with increased Fas and DR5 death receptor expression did not selectively 
accumulate in the 7AAD+ (dead and dying) B cell population at 10 days after infection 
suggesting against a contribution of death receptor signaling to B cell death at this stage 
of infection.  
 
Discussion 
Infection of C57BL/6 mice with T. brucei results in severe deletion of splenic 
transitional, marginal zone and follicular B cells [75], but an increase in the number of 
CD5lowCD11b+IgM+, putatively B1 B cells, in the spleen (Fig S1). Splenic elevations of 
B1 B cells suggest that these B cells are not as sensitive to NK mediated deletion as B2 B 
cells, or that their proliferation exceeds their depletion. Depletion of the splenic B2 B 
cells is accompanied by loss of humoral immune responses against newly arising 
trypanosome variant antigenic types [76] showing that the B2 B cells have a critical role 
in mediating this response. We now show that infection-induced deletion of splenic B2 B 
cells and suppression of the trypanosome-specific antibody response does not occur in 
mice lacking the gene encoding the pore forming protein perforin, implicating cell-
mediated cytotoxicity in the deletion process. Importantly, in the absence of perforin, 
infected mice were able to suppress parasite levels in the blood, to maintain their body 
weight and blood packed cell volume, and to survive for much longer than similarly 
infected intact mice, which jointly are characteristics of trypanosomiasis resistance 
[53,55,115]. In addition, the T. brucei infected perforin gene-deleted animals retained B 
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cell follicles and developed high titer IgM and IgG responses against a wide range of 
trypanosome polypeptides in contrast to infected intact mice, which responded to a 
restricted range of trypanosome polypeptides only and which lost this limited response 
and B cell follicles rapidly after infection. An ability to mount high titer and sustained 
IgG responses against trypanosome antigens including VSG is also a characteristic of 
trypanosomiasis resistant animals [53,85,116]. Taken together, these data show that 
abrogation of perforin-dependent cytotoxicity prevents T. brucei-induced deletion of B2 
B cells and greatly increases the resistance of the infected mice to trypanosomiasis. This 
may not be solely linked to improved antibody-mediated control of trypanosome 
parasitemia because B cells also produce regulatory cytokines [117,118,119] which might 
affect the development of life threatening inflammatory responses in the infected animals.  
Two complementary lines of evidence suggest that NK cells are responsible for 
the perforin-dependent deletion of splenic B cells in the T. brucei-infected mice. Firstly, 
transitional and mature B cell populations were similarly depleted in the spleens of intact 
mice and mice lacking genes encoding both the beta and delta chains of the T cell antigen 
specific receptor and thus lacking all T cells and NK T cells.  Secondly, the splenic B2 B 
cells were retained in infected mice from which NK1.1+ cells were removed by repeated 
administration of PK136 monoclonal antibody [107,120], whereas the B cells were 
deleted from infected mice that were administered a control antibody of the same Ig 
class.   
Although NK cells kill virus-infected or transformed cells and do not typically 
delete healthy self-cells, there are instances where this boundary is broached.  Thus NK 
cells have been shown to kill specific CD4+ T cells in mice with acute systemic LCMV 
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infection with resultant suppression of adaptive immunity [121,122]. They have also been 
shown to exacerbate pathology in mice exposed to high dose influenza virus infection 
although the mechanism is not resolved [123].  In addition, NK cells have been shown to 
regulate auto- and allo-reactive lymphocytes [124,125], by pathways that include deletion 
of activated T cells [126,127] and in which perforin-dependent cytolysis is implicated 
[128,129].  In addition, there are several reports that antibody responses are suppressed 
by NK cells [130,131,132] consistent with a role for NK cells in down-regulation of B 
cell responses per se, and with their more profound role in deletion of splenic B2 B cell 
and generalized immunosuppression of humoral immunity documented here.      
Paradoxically, whereas putative B2 B cell destructive NK cells were found to 
accumulate in the spleen of infected mice within a few days of clearing first wave 
parasitemia, splenic NK cell activity against tumor cells decreases precipitously during 
this period [133]. This raises the possibility that B2 B cell and tumor cell destructive NK 
cells belong to distinct subpopulations. In this regard, the activating receptor NKp46 has 
been shown to play an important role in tumor cell killing by NK cells [134,135,136] and 
loss of this activity in T. brucei infected mice [133] correlates, as shown here, with loss 
of splenic NK cells bearing NKp46 and their replacement by, or differentiation to, NK 
cells that lack this receptor. The putative B cell destructive NK cells also lack expression 
of the integrin α2 subunit CD49b of the collagen receptor [137] which distinguishes them 
from mature NK cells, but have increased expression of the death ligand FasL in common 
with activated mature NK cells [138]. In addition, they also have greatly increased  
expression of the cytotoxic granule marker CD107a, which is placed on the cell surface 
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when cytotoxic granule fuse to the plasma membrane during degranulation and hence is a 
functional marker for cell-mediated cytotoxicity [139].  
Activated NKp46- NK cells also arise in the lungs of mice infected with a high 
dose of influenza virus and exacerbate pathology leading to weight loss and death [123]. 
Potent activation of self-destructive NKp46- NK cells by influenza virus- and T. brucei-
infection is unexpected because NKp46 is an activating receptor and a substantial 
decrease in its expression would be expected to decrease rather than elevate NK cell 
activity. However, a loss of function mutation in the gene encoding NKp46 has been 
shown to result in NKp46- NK cells that are hyper-responsive to various stimuli [140]. 
These hyper-responsive NK cells enhance the innate control of cytomegalovirus infected 
cells but decrease activation of virus-specific CD4+ and CD8+ T cells. However, it is 
unclear whether the decreased adaptive immune response results from T cell deletion or 
another mechanism.  
There is little or no information on the mechanism of induction of the B cell-
destructive NKp46- NK cells that arise in T. brucei infected mice, or mice infected with 
other pathogens. They might arise from infection activated mature NK cells as a result of 
ligand induced modulation of the NKp46 receptor or another stimulus, e.g., NKp46 down 
regulation has been reported to result from L-arginine starvation of cultured NK cells 
[141]. Alternatively, the NKp46- NK cells might arise as a separate NK subpopulation 
during normal development as is suggested by the presence of both NKp46+ and NKp46- 
NK cells in the peripheral blood of healthy pigs [142] and in the intestinal mucosa of 
healthy humans [143]. We anticipate that their origin in mice infected with T. brucei can 
33 
 
be resolved by adoptive transfer of tagged NKp46+ and NKp46- NK and subsequent fate 
analysis.  
Identity of the NK cell receptor and ligand interactions that result in B cell-
deletion is also unresolved. NK cell killing is regulated by a balance of receptor and 
ligand interactions that are either activating or inhibitory to the NK cell [144].  The NK 
cells are known to kill target cells that have decreased MHC I on their plasma membrane, 
designated “missing self”.  However, in the case of the T. brucei-infected mice, MHCI 
expression is actually increased on IgM+ cells (Fig S2). We therefore conclude that 
“missing self”, at least in the context of class I MHC molecules, is not involved in 
making these B cells into targets for NK cells. Furthermore, T. brucei-induced B cell 
killing is similar in infected intact mice and in infected mice lacking the gene encoding 
β2 microglobulin (Fig S3) which is required for transport of MHC class I molecules to 
the cell surface, showing that elevated MHCI is not a requirement for B cell killing, and 
indeed that NK cell licensing which occurs during development in the presence of MHCI 
[145] is not required for infection-associated B cell destruction.  NK cells also express an 
FcγIIIA receptor (CD16) and can kill cells with bound immune or auto-immune IgG by 
antibody and cell mediated cytolysis (ADCC). However, although T. brucei infected mice 
generate auto-reactive antibodies [146,147], anti-lymphocyte antibodies have not been 
reported and ADCC is not required for splenic B cell deletion, which is similar in 
infected intact mice and infected mice lacking the gene encoding CD16 (Fig S4). It is 
anticipated that a comprehensive analysis of receptors expressed on the NKp46+ and 
NKp46- NK cells as well as ligands expressed on splenic B1 and B2 B cells in T. brucei-
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infected mice will provide insights into other candidate receptors and target ligands that 
mediate killing of the B2 B cells by the NKp46- NK cells.   
To conclude, we have shown that T. brucei infection of mice induces NK cells 
which deplete splenic B2 B cells resulting in loss of humoral immune competence. 
Phenotypic analysis of the putative B cell destructive NK cells show that they lack 
NKp46 expression in common with pro-pathology NKp46- NK cells that arise in mice 
heavily infected with influenza virus [123].  NK cells arising in T. brucei-infected mice 
require perforin to delete splenic B cells and facilitate the development of cachexia, 
anemia, and ultimately death, central features of trypansomiasis susceptibility that are 
ameliorated or delayed in infected perf-/- mice compared to intact mice. Further 
investigation is needed to identify the cytokines that induce and activate the B cell 
destructive NKp46- NK cells in the infected mice, the trypanosome components that elicit 
their production, the receptor:ligand interactions that mediate B cell killing, and the 
contribution, if any, of infection-induced NK cells to trypanosomiasis susceptibility of 
other host species.  
 
 
Materials and Methods 
Ethics Statement: The study was carried out in strict accordance with the 
recommendations in the Guide for the Care and Use of Laboratory Animals of the 
National Institutes of Health and Guidelines for the Use of Laboratory Animals in 
Research, Teaching and Testing of the International Council for Laboratory Animal 
Science. All animal studies were approved by the Institutional Animal Care and Use 
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Committee, University of Massachusetts, Amherst, MA01003 USA, as documented in 
protocol #s 2010-0028, 2013-0049 and 2013-0050. 
 
Mice and Trypanosomes: Male C57BL/6 (Taconic, Germantown, NY), C57BL/6-
prf1tm1sdz/1 (perforin-/-), B6.129P2-Tcrbtm1momTcrdtm1mom/J (TCR-/-), B6.129P2-
Fcgr3tm1Sjv/J (CD16-/-) and B6.129P2-B2mtm1Unc (β2microglobulin-/-) mice (Jackson 
Laboratory, Bar Harbor, ME), (7-9 week old) were housed under barrier conditions. Mice 
were infected by intraperitoneal (i.p.) injection of 5000 exponentially growing 
pleomorphic Trypanosoma brucei Antat 1.1E or sham infected by i.p., injection of 
Dulbecco’s Phosphate Buffered Saline (DPBS; GIBCO,Life Technologies). The parasites 
were derived from EATRO 1125 stock [148] and grown in immunocompromised 
C57BL/6 donors (600r from a 127 Cesium source 24 hours prior to i.p. injection of 
cryopreserved parasites).  Parasitemia was assessed in tail blood by dilution in DPBS and 
counting using a hemocytometer.  
 
Mouse Weight and Packed cell volume measurements: Weight was assessed using a 
Ohaus™ brand digital scale. Packed cell volume was calculated as the percent of packed 
red blood cells to serum volume after spinning blood in heparinized capillary tubes in a 
hematocrit centrifuge (ADAMS MHCTII; BD, San Diego) for 8 minutes. 
 
Antibodies: Flow Cytometry –Avidin-APC-Cy7 (San Diego), anti-DR5-biotin (clone 
MD5-1), anti-FasL-PE (clone MFL3), anti-Fas-PE-Cy7 (clone 15A7), anti-H2kb-PE 
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(clone eBM2a), anti-NKp46-PE (clone 29A1.4), anti-IgM-PE (clone II/41), anti-NK1.1-
APC (clone pk136), anti-TRAIL-biotin (clone N2B2), anti-CD11b-APC-Cy7(clone 
M1/70), anti-CD23-APC-Cy7 (clone B3B4), anti-CD23-FITC (clone B3B4), anti-CD45R 
(B220)-FITC (clone RA3-6B2), anti-CD93–APC (clone AA4.1),  anti-CD107a (clone 
1D4B) purchased from eBioscience (San Diego, CA);  anti-CD5-APC (clone 53-7.3) 
anti-CD21-APC (clone 7G6), anti-CD49b FITC (clone DX5) purchased from BD 
Biosciences (San Diego, CA); 7-amino-actinomycin D (7AAD) purchased from EMD 
Chemicals (San Diego, CA). IFA - Anti-MOMA-1(biotin) AbCam (Cambridge MA); 
Avidin-FITC, BD Pharmingen (San Diego, Ca); anti-human/mouse CD45 (B220) 
eBiosciences (SanDiego, Ca).   
 
 Cell isolation and flow cytometric analysis: Mice were killed by lethal CO2 inhalation, 
spleens excised and mechanically dissociated in cold FACS Buffer (1.0% fetal bovine 
serum, FBS, [Atlanta Biologicals] in DPBS). Cell pellets prepared by centrifugation (500 
g, 10 min, 4oC) were suspended in 10ml of cold ammonium chloride lysis buffer (ACK; 
0.15M NH4Cl, 1.0 mM KHCO3, 0.1mM Na2-EDTA) and incubated for 4 minutes on ice 
to lyse red blood cells.  Remaining leukocytes were pelleted as above, washed twice in 
DPBS and suspended in FACs buffer. Aliquots (100 µl) containing 106 cells were added 
to the wells of a 96 well V bottom plate, stained with combinations of specific 
monoclonal antibodies against B cell, T cell and NK cell differentiation antigens (listed in 
Table 1) and analyzed by multicolor flow cytometry as described by us [75] . Briefly, 
cells were incubated with Fc block (anti-CD16/CD32 Fc III/II, eBioscience, San Diego, 
CA; 1:1000 dilution) for 20 minutes at 4°C, pelleted, resuspended in 100 µl aliquots of 
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biotin- or fluorochrome-conjugated primary antibodies (listed above)  for 30 minutes at 
4°C, washed twice in cold FACs buffer, resuspended in 100 µl aliquots of FACs buffer 
with or without streptavidin (SA) conjugated fluorochromes and incubated for an 
additional 30 minutes at 4°C.  Samples were washed twice and resuspended in 300 µl 
FACs buffer with 1 µg of 7AAD, a fluorescent DNA intercalating agent that binds to 
DNA in membrane permeable (dead or dying) cells, (EMD Chemicals, San Diego, CA).  
Analyses were performed using a flow cytometer (LSRII BD Biosciences, San Jose, CA) 
and data processed using FLOWJO software (Tree Star Inc., Ashland, OR) to determine 
the percentages of 7AAD- and where stated also 7AAD+ cells in fluorochrome-tagged 
subsets. The total number of cells in each population was determined by multiplying the 
percentages of subsets within a series of marker negative or positive gates by the total 
cell number of viable leukocytes in the donor spleen.  
 
Immunofluorescence staining of the mouse spleen: Spleens from uninfected and infected 
C57BL/6 and Perf-/- mice were embedded in OCT (Sakura Finetek, Torrance, CA), frozen 
in dry ice, stored frozen at -80°C and incubated at -20°C for 30 minutes before cryostat 
sectioning. Frozen sections (10) µm were cut and adhered to Poly-Prep slides (Sigma-
Aldrich, St.  Louis, MO), air dried and fixed in ice cold acetone for 10 minutes. Slides 
were blocked with 5% bovine serum albumin (BSA) and Fc blocker CD16/CD32 
(eBioscience) for 30 minutes, then stained with biotin conjugated antibody MOMA-1 at 
room temperature for one hour. Sections were washed and treated for one hour at room 
temperature with Avidin FITC and antibody B220.  Stained sections were washed, air 
dried at room temperature and mounted with ProLong® Gold antifade reagent (Life 
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Technologies) and covered with glass coverslips (Corning). All the slides were read on a 
Zeiss MOT200o inverted microscope with a Zeiss apotome at 20x magnification.  
 
NK cell depletion [108,110]: Mice were injected intraperitoneally with 500 ug anti-
NK1.1  IgG2a monoclonal antibody purified from hybridoma (PK136, ATCC Manassas, 
Virginia) culture supernatant by Protein G chromatography, or with an irrelevant control 
IgG2a antibody (M9144, Sigma-Aldrich). Treatments were repeated on days 4 and 7 after 
the first injection of anti-NK1.1 and splenic B cell, T cell and NK cell populations 
assessed on days 3, 7 and 10 using antibody staining and multicolor flow cytometry as 
described above. 
 
Western Blot analysis of trypanosome-polypeptide specific antibodies in mouse serum: 
Parasite lysate was prepared by suspending 108 DEAE52 purified [149] washed T. brucei 
AnTat 1.1E in 5 ml lysis buffer (DPBS, containing 0.4%NP40 and protease inhibitor 
cocktail [Complete mini tablets, Roche, Indianapolis, IN]). Insoluble material was 
removed by centrifugation at 1000g for 5 mins.  An aliquot (600ug protein content) of 
trypanosome lysate was fractionated by reducing SDS-PAGE on a 10% polyacrylamide 
gel in a single gel-spanning slot and transferred to a polyvinylidene difluoride membrane 
using a mini trans-blot transfer apparatus (Bio-Rad) according to the manufacturer’s 
protocols. The membrane was blocked with 5% nonfat milk in (10 mM Tris, pH 8.0, 150 
mM NaCl, 0.5% Tween 20; TBST) for 60 min, washed once with TBST, inserted in a 
slot blot apparatus (Mini Protean Multi Screen II, Biorad) and serum, prepared from 
blood of control and trypanosome-infected mice (1:200 dilution, 600 µl/slot), was added 
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to individual slots and incubated at 4 °C for 2 h. Membranes were washed three times 
(10ml  TBST, room temperature, 10 min) and incubated with horseradish peroxidase-
conjugated anti-mouse IgM, or IgG1 antibodies (ABCAM 0.6 µg antibody/ml TBST) for 
1 hour, then washed 3 times with TBST before developing with chemiluminescence 
substrate (ThermoPierce).   
 
Enzyme linked immunosorbent assay (ELISA) of trypanosome-specific antibodies: Wells 
in a 96 well plate (NUNC) were coated with 0.1 µg T. brucei Antat1.1E NP40 extract 
(prepared as above) in 100 µl DPBS containing 0.05% NP40, washed with ELISA wash 
buffer (PBS + 1% bovine serum albumin [BSA] + 0.05% TWEEN20) and non-specific 
protein binding sites were blocked by incubation with 200 µl aliquots of PBS + 1% BSA. 
Aliquots (100 µl) of control and post-infection mouse serum diluted in DPBS were added 
to each well, incubated for 2 hours at room temperature and wells were washed 3 times 
with ELISA wash buffer to remove unbound serum immunoglobulins. Bound antibodies 
were revealed by addition of biotinylated anti-mouse IgM or anti-mouse IgG (BD 
biosciences) to each well and bound second step antibody was quantified after washing 
by incubation with avidin-conjugated Horse radish peroxidase (BD biosciences).  
Captured antibody was visualized with Ultra TMB ELISA (Thermo scientific) and 
absorbance readings were made at 450nm, using a 96 well plate spectrophotometer. 
 
Statistics: Cell population and other data obtained from infected animals and from non-
infected controls were subjected to two-tailed T tests with significant differences reported 
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as follows: p≤0.05, (**) p≤0.01, (***) p≤0.001.  Differences among multiple groups were 
analyzed using ANOVA and means were compared using Tukey’s honest significant 
difference (HSD) test when p≤0.05 (GraphPad Prism v.4.0, GraphPad Software Inc. San 
Diego, CA).  
 
 
 
  
Fig. 3 Distribution of B220+ B cells 
and MOMA+ macrophages in 
spleens of intact and perforin-/- 
mice infected with T. brucei. Thin 
sections (10 µm) of OCT embedded 
frozen mouse spleens, were air dried, 
fixed in acetone, rehydrated and 
stained with anti- B220 (green) to 
detect B cells and anti-MOMA (red) 
to detect marginal metallophilic 
macrophages.  For images presented 
in this figure, the slides were stained 
and read on the same day on a Zeiss 
MOT200o inverted microscope with 
a Zeiss apotome at 20x 
magnification.  Scale bars, 50 
micrometers. A– Uninfected 
C57BL/6 mice; B – uninfected perf-/- 
C57BL/6 mice; C,E C57BL/6 mice 
infected for 10 and 30 days with T. 
brucei AnTat 1.1E; D,F Perf-/- 
C57BL/6 mice infected for 10 and 30 
days with T. brucei AnTat 1.1E.  
Results are representative of 5 mice 
studied in each group. 
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Fig. 2.3 Distribution of B220+ B cells and MOMA+ macrophages in spleens of intact and perforin-/- mice 
infected with T. brucei. Thin sections (10 µm) of OCT embedded frozen mouse spleens, were air dried, fixed in 
acetone, rehydrated and stained with anti- B220 (green) to detect B cells and anti-MOMA (red) to detect marginal 
metallophilic macrophages.  For images presented in this figure, the slides were stained and read on the same day 
on a Zeiss MOT200o inverted microscope with a Zeiss apotome at 20x magnification.  Scale bars, 50 micrometers. 
A– Uninfected C57BL/6 mice; B – uninfected perf-/- C57BL/6 mice; C,E C57BL/6 mice infected for 10 and 30 
days with T. brucei AnTat 1.1E; D,F Perf-/- C57BL/6 mice infected for 10 and 30 days with T. brucei AnTat 1.1E.  
Results are representative of 5 mice studied in each group. 
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Fig. 2.4 Detection of trypanosome antigen specific antibodies by ELISA and Western blotting. Trypanosome 
lysate was coated on wells of an ELISA plate and used to detect trypanosome antigen specific antibodies of the IgM 
(A) and IgG (C) classes in dilutions of serum from groups of uninfected (naïve) mice and mice that had been 
infected for 10, 20 or 30 days with T. brucei AnTat 1.1E (n=6/group). Trypanosome lysate was subjected to SDS-
PAGE, transferred to membrane and stained with pooled serum from a group of uninfected mice (n=6), or mice 
infected with T. brucei AnTat 1.1E for 10, 20 or 30 days as indicated (n=6/group) to detect polypeptide-specific 
antibodies of the IgM (B) and IgG (D) classes. Results are representative of results obtained in individual mice of 
each group in 2 identical experiments. 
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Fig 2.8 Expression of death receptors FAS and DR5 on viable (7AAD-) and membrane compromised (7AAD+) 
IgM+ spleen cells during infection with T. brucei Antat1.1E. Splenocytes from C57BL/6 mice at day 10 post infection 
with T.brucei Antat1.1E were stained with the vital dye 7AAD and mAbs specific for Fas, DR5 and IgM and analyzed by 
flow cytometry.   (A) Fas expression on 7AAD- IgM+ cells; (B) Fas expression on 7AAD+ IgM+ cells; (C) DR5 
expression on 7AAD- IgM+ cells; (D) DR5 expression on 7AAD+ IgM+ cells. Blue lines present results obtained with 
cells from naïve animals, red lines present results obtained with cells from infected animals.  Results are representative of 
3 identical experiments. 
 
49 
 
  
Fig 2.9 Splenic IgM+, B-1 cells expand within infected mouse spleens.  IgM positive splenocytes from naïve 
C57BL/6 mice and mice infected 10 or 20 days earlier with T.brucei Antat1.1E were further subdivided based on 
their expression of CD11b and CD5.  (A) Representative flow cytometry plots showing the gates used to identify 
CD11b+ and CD5+, IgM+ splenocytes.  (B)  Data are presented as the mean number and standard deviation of IgM+, 
CD5lo, CD11b+ splenocytes and (C) IgM+, CD5+, CD11b- splenocytes from 3 mice per group.  Significance 
(*p<0.05) is determined using a one way ANOVA and Tukey’s multiple comparison test comparing uninfected 
controls to infected mice. Results are representative of 2 identical experiments. 
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Fig 2.10 Expression of class I MHC on IgM+ cells on naïve and T. brucei Antat1.1E-infected C57BL/6 mice. 
IgM positive splenocytes from naïve C57BL/6 mice and mice infected 10 days earlier with T.brucei Antat1.1E 
were stained with monoclonal antibody specific for MHCI and analyzed by flow cytometry.  Blue lines represent 
cells from naïve animals, red lines represent cells from infected animals. Results are representative of 3 identical 
experiments. 
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Table 1 B cell, NK cell and NKT cell differentiation antigens defined by 
specific monoclonal antibodies 
 
Cell Type Differentiation Antigen Expression 
Type 1 Transitional B cell B220+, AA4.1+, CD23-, IgM+ 
Type 2 Transitional B cell B220+, AA4.1+, CD23+, IgMhi  
Type 3 Transitional B cell B220+, AA4.1+, CD23+, IgMlo 
Marginal Zone B cell IgM+, AA4.1-, CD23lo, CD21+ 
Follicular B cell IgM+, AA4.1-, CD23hi, CD21+ 
B1-a B Cell IgM+, AA4.1-, CD5+, CD11b- 
B1-a derived B cell IgM+, AA4.1-, CD5+, CD11b+ 
B1-b B cell IgM+, AA4.1-, CD5-, CD11b+ 
Natural Killer cell CD3-, NK1.1+ 
Natural Killer T cell CD3+, NK1.1+ 
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CHAPTER III 
NK CELL AND PERFORIN DEPENDENT DEPLETION OF CD8 T CELLS IN 
TRYPANOSOMA BRUCEI INFECTED MICE 
 
Abstract 
Trypanosoma brucei is a highly antigenically variable flagellated protozoan that causes fatal 
disease in people and livestock. Infected trypanosomiasis susceptible hosts develop severe 
immunodepression which compromises their capacity to control the on-going trypanosome 
infection and increases their susceptibility to secondary infections. Using a C57BL/6 mouse 
model of human and animal African trypanosomiasis we have shown in chapter 1 that loss of 
humoral immune competence results from depletion of splenic B lymphocytes by a novel NKp46- 
population of natural killer (NK) cells and requires expression of the gene encoding the pore 
forming protein perforin but not that encoding the low affinity Fcγ receptor, CD16, consistent 
with cell mediated, but not antibody dependent, cytotoxicity. We show here using the same T. 
brucei AnTat1.1E infection model, gene knock strains of mice, and multicolor flow cytometry 
that T. brucei infection induced NK cells also deplete splenic CD8 T cells with similar kinetics to 
B2 B cell depletion and with a similar requirement for perforin gene expression and lack of 
requirement for CD16 gene expression.  CD4 T cells were less affected than CD8 T cells. Unlike 
depletion of B2 B cells, NK cell dependent depletion of CD8 T cells required host expression of 
genes encoding MyD88 and TRIF which are adaptor proteins for Toll-like receptor signaling, 
suggesting that this pathogen molecular pattern recognition system is specifically involved in the 
CD8 T cell recognition rather than NK cell activation. Repeated injection of naïve mice with T. 
brucei AnTat 1.1E lysate did not elicit CD8 T cell or B cell destructive NK cells. These results 
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are discussed in the context of the regulation of adaptive and innate immune responses during 
acute infections.  
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Introduction 
Trypanosoma brucei is a highly antigenically variable protozoan parasite that resides in the blood 
plasma, tissue fluid and cerebrospinal fluid of its mammalian hosts.  It is transmitted by the bite 
of the tsetse fly (spp. Glossina), and is endemic in the tsetse habitat which encompasses 10 
million square kilometers of the humid and semi-humid regions of Africa. T. brucei contributes to 
animal African trypanosomiasis (AAT) and causes human African trypanosomiasis (HAT), 
diseases that constrain food production and socio economic development of sub-Saharan Africa.  
As an adaptation to life in the host extracellular fluids each T. brucei is coated with an almost 
contiguous monolayer of a single species of variable surface glycoprotein (VSG) which is 
encoded by a single VSG gene. This is selected from a large repertoire of genomic VSG genes 
and pseudogenes and varied stochastically and infrequently resulting in the generation of 
antigenic variants [150]. Some of the antigenic variants that are generated do not react with, and 
hence evade clearance by, VSG-specific antibodies that are induced by the dominant VSG types 
in the trypanosome population. The surviving antigenic variants expand to restore the parasite 
burden upon antibody mediated elimination of the dominant VSG types, a process that results in 
recurring waves of parasitemia.   
Mammal hosts vary in their ability to control infections with T. brucei and other African 
trypanosomes. Some hosts, e.g., Cape buffalo, which were selected by co-evolution with African 
trypanosomes and tsetse vectors, carry the parasite with few or no signs of disease [53], while 
hosts that were not selected to resist the disease e.g., humans, livestock and mice, develop severe 
inflammation, cachexia, anemia, and immune system dysfunctions which result in life threatening 
immunopathology and increased susceptibility to secondary infections [151]. Analyses in murine 
models of AAT and HAT show that life threatening inflammation is associated with a polarized 
TH1 T cell response [73,152] and an inadequate regulatory IL-10 response [153] which results in 
the early and sustained production of pro-inflammatory cytokines, IFNγ and TNFα. IFNγ 
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supports TH1 T cell polarization, which consequently is self-sustaining in the absence of 
regulatory cytokines.  TH1 T cell polarization is additionally facilitated by production of IFNγ by 
CD8+ T cells in response to trypanosome cytoskeleton associated T lymphocyte triggering factor 
[154] and by infection-induced deletion of splenic B2 B cells including marginal zone B cells 
[75,155] which produce IL-10 [156].  
The depletion of B cells in T. brucei infected mice is mediated by natural killer (NK) cells and is 
dependent on expression of the pore forming molecule perforin consistent with cell mediated 
cytotoxicity.  Thus deletion of NK cells from the infected mice by administration of NK1.1 
specific antibody prevents infection induced depletion of transitional and mature splenic B2 B 
cells, and the B cells are not deleted from the spleens of infected perforin-/- C57BL/6 mice. Not 
only do the T. brucei infected perforin-/- mice mount high titer IgG antibody responses against 
many trypanosome antigens unlike similarly infected intact mice, they maintain their body weight 
and blood packed cell volume showing that they do not develop cachexia and anemia. Taken 
together these observations suggest that infection induced NK cell cytotoxicity has broad 
immunopathologic consequences and hence that NK cells may affect leukocytes in addition to B2 
B cells.  
 
It has been established that NK cells that accumulate in the spleen of mice undergoing B cell 
apoptosis have an activated immature phenotype. They do not express the integrin α2 chain 
CD49b of the collagen receptor, or the NK cell activating receptor NKp46, both of which are 
characteristically expressed by mature NK cells. They do however, have high expression of the 
death ligand FasL in common with activated mature NK cells as well as high surface expression 
of the cytotoxic granule marker CD107a indicating degranulation [157] which is associated with 
cell mediated cytotoxicity.  
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It has been recently shown that NKp46-, CD107a+ cells predominate in the lungs of mice acutely 
infected with influenza virus and that depletion of the NK cells significantly reduces mortality 
and reduces lung tissue damage[123]. In addition, during acute infections of mice with 
lymphocytic choriomeningitis virus, NK cells mediate mortality and lung pathology via a 
cytolytic depletion of antigen specific CD4+ T lymphocytes and downstream inactivation of 
antigen specific CD8+ T cells [121,145].  The observation that B cell destructive NK cells arising 
in T. brucei infected mice have a similar differentiation antigen phenotype to the T cell 
destructive NK cells that arise in mice with acute virus infections raises the possibility that the 
cells might also have functional similarity, i.e., that T. brucei infection-induced NK cells might 
kill T cells as well as B cells. We investigate this possibility here using mice in which NK1.1+ 
cell presence and function is modulated through treatment with anti-NK1.1 specific monoclonal 
antibody and through knock out of genes encoding CD1d, an MHC-1 like molecule required for 
natural killer T (NKT) cell development [158], perforin which is required for cell mediated 
cytotoxicity [159], and CD16 which is required for antibody dependent cell mediated cytotoxicity 
[160]. In addition we investigate the possible role of signaling thorough Toll like receptors in 
deletion of B cells and T cell by T. brucei-infection induced NK cells.  
Toll like receptors (TLRs) recognize specific molecular patterns of microbial pathogens referred 
to as pathogen associated molecular patterns (PAMPS).  TLRs are located on the plasma 
membrane (TLRs 1, 2, 4-6, 11), where they recognize components of foreign microorganisms, or 
intracellularly (TLRs 7, 8, 9, 3), where they recognize Viral nucleic acids [161].  Signaling 
through Toll like receptors induce inflammatory responses including the production of type 1 
interferons and plays an important role in innate immunity to bacterial, fungal, and viral 
pathogens as well as playing important role in homeostasis and tolerance in the liver, and in 
systemic autoimmunity[162,163,164].  Natural killer cells possess TLRs and are stimulated to 
produce INFγ upon ligation of TLRs [165].  TLRs signal through the adaptor proteins MyD88 or, 
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in the case of TLR3, through the TIR-domain-containing adapter-inducing interferon-β 
(TRIF)[165,166,167].  The majority of TLRs require MyD88 for signaling (TLR1, TLR2, TLR5, 
TLR6, TLR11 on the cell surface, and TLR7, TLR8, TLR9, TLR13 intracellularly).  Whereas the 
intracellular TLR3 does not require MyD88, but requires TRIF. Furthermore, TLR4, which 
localizes at both the plasma membrane and in endosomes, can signal through TRIF in the absence 
of MyD88[168]. Here we show that Both MyD88 and TRIF are required for depletion of CD8+ T 
cells during T. brucei infection. 
 
Results 
Experimental Strategy 
All studies reported below were done on individual strains of mice and were repeated at least 3 
times for each strain.  Infections, in each case were with 5000 exponentially growing T. brucei 
Antat 1.1E which were grown from a cryostabilate for 4 days in immunocompromised (600 r) 
C57BL/6 mice prior to injection into the experimental mice. Control mice were uninfected age 
and gender matched and were received on the same day as the mice receiving T. brucei 
infections. In all cases spleen cell numbers and types from infected mice were compared 
statistically to those of matched uninfected mice of the same strain which are considered to 
represent day 0 of infection. The studies therefore report the impact of T. brucei AnTat1.1E on 
splenic T cells in each strain of mice. Comparative infections were not performed between strains 
of mice although results are discussed in the context of strain differences.  The impact of 
infections on the splenic B cell content of the same mice are reported previously in this thesis.  
 
T. brucei infection induces depletion of splenic CD8+ T cells in C57BL/6 mice 
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Depletion of splenic B2 B cells occurs after remission of the first parasitemic wave in C57BL/6 
mice which occurs between 7 and 8 days after infection with 5000 exponentially growing T. 
brucei AnTat 1.1E and is almost complete by 10 days post infection [75] (and described in the 
previous chapter).  A comparison of results presented in Figure 1 panels A and B versus panels C 
and D show that the proportion of CD4+ T cells (CD3+, CD4+, CD8-) remains similar in a 
representative infected and uninfected mouse, whereas proportion of CD8+ T cells (CD3+, CD4-, 
CD8+) decreases in the infected mouse compared to the uninfected mouse. Results presented in 
Figure 1 also show that numbers of splenic T cells (CD3+) and CD8+ T cells significantly 
decreased on days 10, 20 and 30 after infection of C57BL/6 mice with T. brucei AnTat 1.1E (Fig 
1 Fig 1A-D, E,G). In contrast, the number of splenic CD4+ T cells did not  decrease significantly 
on days 10 and 30 after infection (Fig. 1F), although it was decreased significantly at 20 days 
after infection (Fig. 1G).  As with splenic B cells (previous chapter), there was no significant 
difference in the numbers of splenic T cells (CD3+), CD4+ T cells and CD8+ T cells in mice that 
had been uninfected 7 days earlier and those infected 7 days earlier with T. brucei AnTat 1.1E 
(data not shown).  
CD8+ T cells are not deleted from the spleens of C57BL/6 mice depleted of NK1.1+ cells  
Removal of NK and NKT cells by administration of anti-NK1.1 monoclonal antibody to 
C57BL/6 mice on days -1, 3 and 7 post infection with 5000 T. brucei AnTat1.1E prevents the 
depletion of splenic B2 B cells (previous chapter). Results presented in Figure 2 show that T cells 
(CD3+), and CD8+ T cells are not depleted from the spleens of NK1.1+ antibody treated mice that 
had been infected for 10 days with T. brucei AnTat1.1E.  Thus individual antibody treated 
uninfected and T. brucei infected mice had similar proportional representation of CD4+ and CD8+ 
T cells (Fig 2, panels A-D), and similar numbers of total T cells, CD4+ T cells and CD8+ T cells. 
The anti-NK1.1 protocol depletes both NK cells (CD3- NK1.1+) and natural killer T (NKT; CD3+ 
NK1.1+) cells (Fig 3).  
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CD8+ T cells are depleted from the spleens T. brucei infected CD1d-/- C57BL/6 mice 
  
Mice lacking the gene encoding CD1d were used to determine the contribution of NKT cells to 
the T. brucei infection induced depletion of CD8+ T cells. CD1d is specialized to present 
glycolipid antigens to NKT cells and in its absence NKT cells do not develop, whereas 
development of other T cells and NK cells is not prevented [169,170].  Despite the absence of 
NKT cells, CD8+ T cells are depleted proportionally and numerically from the spleens of CD1d-/- 
C57BL/6 mice infected 10 days earlier with 5000 T. brucei AnTat 1.1E (Fig 4). There was no 
significant difference in the total number of T cells CD3+ or CD4+ T cells in the day 10 infected 
mice compared to uninfected mice. These data suggest a critical role for NK cells but not NKT 
cells in Trypanosome induced depletion of CD3+ and CD8+ T cells. 
 
CD8+ T cells are not depleted from the spleens of T. brucei infected perforin-/- C57BL/6 
mice but are depleted from the spleens of T. brucei infected CD16-/- mice.  
 
We have previously shown that B2 B cells are depleted from the spleens of intact C57BL/6 mice, 
but not from the spleens of perforin-/- C57BL/6 mice infected with 5000 T. brucei Antat 1.1E 
(previous chapter). This also proved to be the case with splenic CD8 T cells. There was neither a 
proportional nor a numerical decrease in T cells (CD3+), CD4+ T cells, or CD8+ T cells from the 
spleens of the infected perforin-/- mice as compared to uninfected perforin-/- mice up to 60 days 
after infection with 5000 T. brucei AnTat 1.1E. Results for 10 days post infection are presented in 
Figure 5.  
NK cell mediated cytotoxicity is regulated by the interaction of an array of inhibitory and 
activating receptors expressed on the surface of the NK cells with ligands on the target cell [144], 
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and is facilitated by the interaction of target cell bound antibody with the activating receptor 
CD16 on NK cells [160], referred to as antibody dependent cell mediated cytotoxicity (ADCC).  
CD16 is the low affinity receptor for the Fc portion of some IgGs. Results presented in Fig 6 
show that CD8+ T cells are proportionally and numerically decreased from the spleens of CD16-/- 
C57BL/6 mice 10 days after infection with 5000 T. brucei AnTat 1.1E. Although the mean 
numbers of T cells (CD3+) and CD4+T cells were reduced relative to those in uninfected mice 
these reductions were not statistically significant. 
 
Expression of MyD88 and TRIF is required for T. brucei infection induced depletion of 
splenic CD8+ T cells 
Mice which are lacking the gene encoding the adaptor protein MyD88 or TRIF, and thus cannot 
signal through TLRs (excepting TLR3 in the case of MyD88-/-, and only TLR3 in the case of 
TRIF) were infected with T. brucei.  At day 10 post infection both MyD88-/- and TRIF-/- mice had 
maintained numbers of total CD3+, Cd4+ and CD8+ T cells to levels similar to those in 
uninfected MyD88-/- or TRIF-/- mice.  Though both MyD88-/- and TRIF-/- mice have low numbers 
of T cells as compared to intact C57BL/6 mice, these data suggest that TLR signaling is 
important for loss of CD8+ T cells during T. brucei infection.  
Trypanosome lysate injections do not induce depletion of Splenic CD8+ T cells in C57BL/6 
mice  
Freeze thaw lysate of T. brucei was prepared in the presence of protease inhibitors.  C57BL/6 
mice were administered lysate from 108 T. brucei via 3 retro-orbital injections on consecutive 
days.  Numbers of CD3+, CD4+ and CD8+ T. cells were unchanged in mice having received 
T.brucei lysate as compared to animals that  did not receive injections of lysate.  These data 
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suggest that soluble portions of T. brucei in the blood plasma are not sufficient to cause a 
depletion of T cells in C57BL/6 mice.  
Discussion 
We have previously established that during T. brucei innfection NKp46- NK cells are responsible 
for depletion of splenic B2 B cells and loss of humoral immune competence. B cell deletion 
occurs after remission of the first parasitemia wave, results from perforin-dependent NK cell 
mediated cytotoxicity, and does not involve ADCC (previous chapter). We show here that T. 
brucei infection induced NK cells also deplete splenic CD8+ T cells and do so with similar 
kinetics to the depletion of B2 B cells. Thus at the peak of first wave parasitemia i.e., by 7 days 
after infection with 5000 exponentially growing T. brucei AnTat 1.1E, the number and class 
composition of splenic T cells is similar to that in uninfected mice, whereas by 3 days later the 
number of CD8+ cells in the spleen is decreased by about 90% compared to uninfected mice. As 
with infection-induced depletion of B2 B cells, the depletion of CD8 T cells is mediated by 
NK1.1+ cells and does not occur in mice that lack the gene encoding perforin. Furthermore, 
depletion of the CD8 T cells does not require NKT cells, which we show here using mice that do 
not express the gene encoding CD1d which is required for NKT cell development [158]. In 
addition, similar to depletion of splenic B cells, the depletion of splenic CD8 T cells occurs in 
mice that lack the gene encoding CD16 and which therefore do not support FcγR-dependent 
ADCC.  
The activation of NK cells that subvert lymphocyte responses and adaptive immunity is not 
restricted to T. brucei infection. Virus specific CD8+ cells are decreased during acute mouse 
cytomegalovirus (MCMV) infection by NK cell- [140] and perforin- [121,145] dependent cell 
mediated cytotoxicity. In addition, both virus and T. brucei infection-induced NKp46- NK cells 
contribute to host pathology. Thus inactivation of the cytotoxic mechanism in T. brucei-infected 
perforin-/- mice sustains splenic B2 B cells (previous chapter) and CD8 T cells (shown here), 
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prevents weight loss and the development of anemia and greatly extends survival compared to 
similarly infected intact mice (previous chapter), whereas depletion of NK cells (predominantly 
NKp46- NK cells) from mice acutely infected with influenza virus abrogates lung tissue 
pathology and results in lower mortality rates[123]. NKp46 is an NK cell activating receptor, 
which reacts with viral hemagglutinins [171] and with unknown ligands expressed by tumor cells, 
antigen presenting cells, and pancreatic beta cells [172]. However, despite its designation as an 
activating receptor, NKp46 also has a critical role in preventing over-activation of NK cells. 
Thus, NKp46- NK cells that arise in mice bearing the natural cytotoxicity triggering receptor 1 
mutation noe which prevents placement of NKp46 on the cell surface but not its synthesis, are 
hyper-responsive to a variety of stimuli. They are protective during MCMV infection but at the 
expense of adaptive immunity which they decrease by deleting virus responsive T cells [140].  
Depletion of self-reactive lymphocytes by NKp46- NK cells may also be an important feature of 
self-tolerance, and lack of expression of NKp46 is a feature of NKs in tolerance organs i.e., 
organs in which antigen presentation results in tolerance instead of an adaptive immune response, 
such as intestine, uterus, and liver [140,148]. Little is known regarding the induction, activation 
and specificity of NKp46- NK cells in infected mice and in tolerogenic organs. 
The correlation between development of lymphocyte destructive NK cells, and the depletion of 
splenic CD8 T cells and B2 B cells and clearance of first wave parasitemia in T. brucei infected 
mice is consistent with NK cell activation by products (antibodies, cytokines, chemokines etc.,) 
of responding leukocytes, or by components of trypanosome that are released during immune 
clearance, or combinations of these. In this regard, depletion of the splenic B2 B cells and CD8 T 
cells, is associated with loss of expression of NKp46 and CD49, and gain of expression of FasL 
and CD107a, i.e., loss of some mature NK cell differentiation antigens and acquisition of markers 
of activation and degranulation. It has been recently shown that repeated stimulation of human 
NK cells with antibody and antigen complexes that bind to CD16, which is the low affinity Fcγ 
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receptor, causes down regulation of NKp46 expression [173]. However, while immune 
complexes are certainly present in blood plasma and tissue fluids upon antibody mediated 
clearance of trypanosomes, loss of B2 B cells occurs in infected CD16-/- mice to a similar degree 
to that in infected intact mice (previous chapter) and hence does not require binding of immune 
complexes to CD16. In addition, activation of NK cells to kill B cells occurs to a similar degree in 
intact mice and mice lacking both T cells and NKT cells, and their activation to deplete CD8 T 
cells occurs to a similar degree in intact mice and mice lacking NKT cells, excluding a 
requirement for T cell and NKT cell derived immune modulators for induction of lymphocyte 
destructive NK cells.  NK cells express Toll-Like receptors (TLRs) that recognize pathogen 
associated molecular patterns [165] as do accessory cells that are important in NK cell activation 
However, while TLRs are unlikely to play a role in activation of B2 B cell destructive NK cells in 
T. brucei infected mice because depletion of splenic B2 B cell populations is similar in intact 
mice and in mice lacking the genes encoding MyD88 or TRIF, which are adaptor protein required 
for TLR signaling, mice lacking MyD88 or TRIF maintain T cells during infection to similar 
levels seen in uninfected MyD88 or TRIF knockout mice suggesting a potential role for TLR 
signaling in NK cell dependant depletion of CD8+ T cells.  
Finally, we have not observed loss of NKp46 expression by NK cells in mice injected 
intravenously, daily for 3 days, with the freeze thaw lysate of 108 T. brucei AnTat 1.1E prepared 
either in the presence or absence of protease inhibitors, and this regime did not result in the 
depletion of splenic B2 B cells or CD8 T cells suggesting against direct or indirect activation of 
the NK cells by water soluble trypanosome components in blood plasma. However, we have 
observed that injection of naïve C57BL/6 mice with day 10 post infection serum from mice 
infected with T. brucei AnTat 1.1E, but not with normal mouse serum, induces a substantial 
portion (40-50%) of splenic NK cells to lose expression of NKp46 and CD49b and to express the 
activation marker CD69, but not FasL or CD107a suggesting partial activation (Hilliard, 
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unpublished). Further study in this system might therefore provide insights into the 
developmental pathway and activation of the NKp46- NK cells.  
Not only is the mechanism of T. brucei infection induced NK cell activation unresolved, so is the 
mechanism of target cell specificity. The T. brucei infection induced NK cells deplete splenic B2 
B cells but not B1 B cells (previous chapter) and, as shown here, also deplete CD8 T cells but not, 
or to a much lesser extent CD4 T cells. NK cells comprise several subpopulations that differ in 
ontogeny and differentiation antigen expression but share regulation by inhibitory and activating 
signals received through an array of receptors that express either inhibitory or activating motifs 
[174]. Hence it is reasonable to hypothesize that activated CD8 T cells and B2 B cells lack, or 
express a lower amount of, an inhibitory ligand for NKp46- NK cell cytotoxicity.  The best 
studied negative regulator of NK cells is MHC class I which signals mouse NK cells through the 
Ly49 family of receptors [175], however the level of expression of MHC I is increased by three 
fold on B2 B cells (previous chapter) and on CD8 T cells (not shown) of C57BL/6 mice infected 
with T. brucei Antat 1.1E, as it is on the B1 B cells and CD4 T cells (not shown), excluding this 
regulatory axis.  MHCI is not the sole ligand for NK cell inhibitory receptors.  2B4 is another 
important inhibitory NK cell receptor, for which the ligand (CD48), is expressed on 
hematopoietic cells.  Altered expression of CD48 on target cells or of 2B4 on NK  cells results in 
a lack of inhibitory signal to the NK cells and killing[176].  In the future, it will be informative to 
assess the expression of known NK cell activating and inhibitory receptors as well as expression 
of their cognate ligands on the activated B cells and T cells of T. brucei infected mice. 
 
Materials and Methods 
Ethics Statement: The study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and 
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Guidelines for the Use of Laboratory Animals in Research, Teaching and Testing of the 
International Council for Laboratory Animal Science. All animal studies were approved by the 
Institutional Animal Care and Use Committee, University of Massachusetts, Amherst, MA01003 
USA, as documented in protocol #s 2010-0028, 2013-0049 and 2013-0050. 
Mice and Trypanosomes: Male C57BL/6 (Taconic, Germantown, NY), C57BL/6-prf1tm1sdz/1 
(perforin-/-), , B6.129P2-Fcgr3tm1Sjv/J (CD16-/-), B6(C)-Cd1d1tm1.2Aben/J (CD1d-/-)(Jackson 
Laboratory, Bar Harbor, ME) add MyD88-/- and TRIF-/- (generously provided by Katherine 
Fitzgerald, University of Massachusetts Medical School), (7-9 week old) were infected by 
intraperitoneal (i.p.) injection of 5000 exponentially growing pleomorphic Trypanosoma brucei 
Antat 1.1E (derived from EATRO 1125 stock, described in[148]) in blood collected from 
immunocompromised C57BL/6 donors (600r from a 127 Cesium source, 24 hours prior to i.p. 
injection of cryopreserved parasites) and diluted in Dulbecco’s Phosphate Buffered Saline 
(DPBS; GIBCO,Life Technologies), or uninfected by i.p., injection of DPBS.  Parasitemia was 
assessed in blood collected from the tail vein during infection by dilution (1:100) in DPBS and 
counting using a hemocytometer. All mice were housed under barrier conditions.  
Cell isolation and flow cytometric analysis: Spleens were dissected from mice that were killed by 
lethal CO2 inhalation and mechanically dissociated in cold FACS Buffer (1.0% fetal bovine 
serum, FBS, [Atlanta Biologicals] in DPBS). Supernatant was collected, cell pellets prepared by 
centrifugation (500 g, 10 min, 4oC) and red blood cells were lysed by re-suspending each spleen 
cell pellet in 10ml of cold ammonium chloride lysis buffer (ACK; 0.15M NH4Cl, 1.0 mM 
KHCO3, 0.1mM Na2-EDTA). Incubations in ACK buffer were for 4 minutes on ice after which 
cells were pelleted as above, washed twice in FACs buffer, re-suspended in FACs buffer and 100 
µl aliquots containing 106 cells were added to the wells of a V bottom plate and stained with 
combinations of specific monoclonal antibodies against B cell, T cell and NK cell differentiation 
antigens (listed in Fig S1) to identify these leukocyte populations and subpopulations by 
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multicolor flow cytometry as described [75] . Briefly, cells were incubated with a 1:1000 final 
concentration Fc block (CD16/CD32 Fc III/II, eBioscience, San Diego, CA) for 20 minutes at 
4°C, pelleted, resuspended with biotin- or fluorochrome-conjugated primary antibodies (listed 
below) for 30 minutes at 4°C, washed twice in cold FACs buffer, resuspended in 100 µl buffer 
with or without streptavidin (SA) conjugated fluorochromes, which detects cell bound 
biotinylated antibodies, and incubated for an additional 30 minutes at 4°C.  Samples were washed 
twice and resuspended in 300 µl FACs buffer with 1 µg of 7-amino-actinomycin D (7AAD), a 
fluorescent DNA dye that binds to membrane permeable (dead or dying) cells, (EMD Chemicals, 
San Diego, CA).  Analyses were performed using a flow cytometer (LSRII BD Biosciences, San 
Jose, CA) and data processed using FLOWJO software (Tree Star Inc., Ashland, OR) to 
determine the percentages of 7AAD-ve and where stated also 7AAD+ve cells in fluorochrome-
tagged subsets. The total number of cells in each population was determined by multiplying the 
percentages of subsets within a series of marker negative or positive gates by the total cell 
number determined for each tissue. Differences among multiple groups were analyzed by 
ANOVA and means were compared using Tukey’s HSD test when p≤0.05 (GraphPad Prism 
v.4.0, GraphPad Software Inc. San Diego, CA). 
Preparation of T. brucei lysate: Parasite lysate was prepared by suspending 108 DEAE52 purified 
[149] washed T. brucei AnTat 1.1E in 5 ml lysis buffer (DPBS, containing 0.4%NP40 and 
protease inhibitor cocktail [Complete mini tablets, Roche, Indianapolis, IN]). Insoluble material 
was removed by centrifugation at 1000g for 5 mins. 
Antibodies and detection reagents: The following antibodies were added to 100 µl aliquots of 106 
Fc-blocked (anti-CD16/CD32 clone 93) leukocytes: anti-CD3-FITC (clone 145-2C11), anti-CD8-
PE (clone 53-6.7), anti-CD4–APC-Cy7 (clone GK1.5 ), anti-IgM-PE (clone II/41), anti-CD23-
PE-Cy7 (clone B3B4), anti-CD45R (B220)-FITC (clone RA3-6B2), anti-CD93–APC (clone 
AA4.1) purchased from eBioscience (San Diego, CA); anti-CD21-APC (clone 7G6) purchased 
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from BD Biosciences (San Diego, CA); 7-amino-actinomycin D (7AAD), (EMD Chemicals, San 
Diego, CA) 
NK cell depletion [177,178] and FasL Blocking: Mice were injected intraperitoneally with 500 ug 
anti-NK1.1  IgG2a monoclonal antibody purified from hybridoma (PK136, ATCC Manassas, 
Virginia) culture supernatant by Protein G chromatography, or with an irrelevant control IgG2a 
antibody (M9144, Sigma-Aldrich). Treatments were repeated on days 4 and 7 after the first 
injection of anti-NK1.1 and depletion of splenic NK1.1+ cells was assessed on days 3, 7 and 10 
using flow cytometry as described above. Blocking of Fas-FasL signaling was performed as 
previously described[179]; anti-FasL MFL4 antibody (Ab) [180] was injected intraperitoneally 
(500 µg per mouse).  
Statistics: Results comparing data obtained from infected animals and from non-infected controls 
were subjected to two-tailed T tests with significant differences reported as follows: p≤0.05, (**) 
p≤0.01, (***) p≤0.001.  Differences among multiple groups were analyzed using ANOVA and 
means were compared using Tukey’s honest significant difference (HSD) test when p≤0.05 
(GraphPad Prism v.4.0, GraphPad Software Inc. San Diego, CA). 
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Fig 3.1 Splenic CD8+ T cells are depleted in C57BL/6 mice infected with T. brucei AnTat 1.1E. Mice were 
infected with 5000 T. brucei AnTat 1.1E. Spleens were taken at days 10, 20 and 30 post infection and T cells 
(CD3, CD4 and CD8) were analyzed using FACS. Uninfected mice were used as controls at each time point. A,B - 
Detection of splenic CD4 and CD8 T cells in a representative naïve C57BL/6 mouse. C,D - Detection of splenic 
CD4 and CD8 T cells in a representative C57BL/6 mouse 10 days after infection. E-G - Mean number of 
cells/spleen+/- 1 standard deviation of: (E) CD3+ (F) CD4+ (G) CD8+T cells (n=3). Day 0 values are the mean of 
all sham infected mice. Significance (*<0.05, **<0.001, ***<0.0001) is determined using one way ANOVA and 
Tukey’s HSD test comparing uninfected to infected mice   
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Fig 3.2 Splenic T cells are maintained in the absence of natural killer cells in C57/BL6 mice infected with T. 
brucei AnTat 1.1E. Mice were infected with T. brucei AnTat 1.1E.  They were treated with anti-NK1.1 mAb on 
days -1, 4, 7 post infection.  Spleens were taken at day 10 post infection and T cells (CD3, CD4 and CD8) were 
analyzed using FACS. Uninfected mice and uninfected mice treated with anti-NK1.1 mAb were used as controls. 
A,B - Detection of splenic CD4 and CD8 T cells in a representative naïve C57BL/6 mouse treated with anti-NK1.1. 
C,D - Detection of splenic CD4 and CD8 T cells in a representative anti-NK1.1 treated C57BL/6 mouse 10 days after 
infection. E-F - Total numbers of: (E) CD3+ (F) CD4+ (G) CD8+T cells/spleen of control untreated mice (-0), 
control NK1.1 specific antibody treated mice (+0) and T. brucei infected NK1.1 specific antibody treated mice (+10). 
Data are presented as mean number of cells/spleen +/- 1 standard deviation (n=3).  Significance (*<0.05, **<0.001, 
***<0.0001) is determined using one way ANOVA and Tukey’s HSD test comparing uninfected controls to infected 
individuals.   
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Fig 2.3 Depletion of NK1.1+ cells Spleens were collected from C57BL/6 mice injected i.p. 4 days earlier with 
500µg of an irrelevant IgG2a mAb (panel A), or 500µg pk136 (anti-NK1.1) mAb (panel B), CD3+ and NK1.1+ 
cells were detected by FACS 
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Fig 3.4 Splenic CD8+ T cells are depleted in CD1d deficient C57BL/6 mice infected with T. brucei AnTat 
1.1E. CD1d-/- C57BL/6 mice were infected with 5000 T. brucei AnTat 1.1E on day 0. Spleens were taken at days 
10, post infection and T cells (CD3, CD4 and CD8) were analyzed using FACS. Uninfected mice were used as 
controls. A,B - Detection of splenic CD4 and CD8 T cells in a representative naïve C57BL/6 mouse. C,D - 
Detection of splenic CD4 and CD8 T cells in a representative C57BL/6 mouse 10 days after infection. E-G - Mean 
number of cells/spleen+/- 1 standard deviation of: (E) CD3+ (F) CD4+ (G) CD8+T cells (n=3). Day 0 values are 
the mean of sham infected mice. Significance (*<0.05, **<0.001, ***<0.0001) is determined using one way 
ANOVA and Tukey’s HSD test comparing uninfected to infected mice   
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Fig 3.5 Splenic CD8+ T cells are maintained in perforin-/- mice infected with T. brucei AnTat 1.1E. Perforin-/- 
C57BL/6 mice were infected with 5000 T. brucei AnTat 1.1E. Spleens were taken at days 10 post infection and T 
cells (CD3, CD4 and CD8) were analyzed using FACS. Uninfected mice were used as controls. A,B - Detection of 
splenic CD4 and CD8 T cells in a representative naïve C57BL/6 mouse. C,D - Detection of splenic CD4 and CD8 T 
cells in a representative C57BL/6 mouse 10 days after infection. E-G - Mean number of cells/spleen+/- 1 standard 
deviation of: (E) CD3+ (F) CD4+ (G) CD8+T cells (n=3). Day 0 values are the mean of uninfected mice. 
Significance (*<0.05, **<0.001, ***<0.0001) is determined using one way ANOVA and Tukey’s HSD test 
comparing uninfected to infected mice   
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Fig 3.6 Splenic CD8+ T cells are depleted in CD16-/- mice infected with T. brucei AnTat 1.1E. CD16-/- 
C57BL/6 mice were infected with 5000 T. brucei AnTat 1.1E on day 0. Spleens were taken at days 10, post 
infection and T cells (CD3, CD4 and CD8) were analyzed using FACS. Uninfected mice were used as controls. 
A,B - Detection of splenic CD4 and CD8 T cells in a representative naïve C57BL/6 mouse. C,D - Detection of 
splenic CD4 and CD8 T cells in a representative C57BL/6 mouse 10 days after infection. E-G - Mean number of 
cells/spleen+/- 1 standard deviation of: (E) CD3+ (F) CD4+ (G) CD8+T cells (n=3). Day 0 values are the mean of 
uninfected mice. Significance (*<0.05, **<0.001, ***<0.0001) is determined using one way ANOVA and Tukey’s 
HSD test comparing uninfected to infected mice   
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CHAPTER IV 
TRYPANOSOMA BRUCEI PLC AND HOST CD1D JOINTLY REGULATE 
INFECTION INDUCED DEPLETION OF SPLENIC B2 B CELLS BY NK CELLS 
 
Abstract 
We have previously shown that depletion of splenic B2 B cells in T.brucei infected mice, which  
suppresses trypanosome specific antibody responses, requires perforin dependent NK cell-
mediated cytotoxicity. Here we show that B2 B cell depletion is regulated by both T. brucei 
variable surface glycoprotein glycosylphosphatidylinositol specific phospholipase C (PLC) and 
host CD1d. Thus splenic B2 B cells were not depleted from C57BL/6 mice infected with PLC-/- T. 
brucei and these mice controlled parasitemia and survived for 125 days post infection (dpi), 
whereas splenic B2 B cells were depleted by a NK1.1+ cell- and perforin-dependent process in 
CD1d-/- C57BL/6 mice infected with the same PLC-/- T. brucei, and the mice died with 
fulminating parasitemia by 35 dpi. Lack of splenic B2 B cell depletion in PLC-/- T. brucei infected 
intact C57BL/6 mice was not due to a protective response because the B cells were rapidly 
depleted from these mice following super-infection 3 to 15 days later with a cloned intact T. 
brucei from the same isolate. Retention of B2 B cells in intact mice infected with PLC-/- T. brucei 
and their loss from CD1d-/- mice infected with the same parasites was associated with differential 
NK cell cytotoxic granule degranulation evidenced by differential expression of CD107a. The 
degranulation marker was highly expressed by NK cells from infected CD1d-/- but not intact mice, 
suggesting the absence of signals that cause NK cell degranulation. Phenotypic analyses of 
splenic NK cells from PLC-/- T. brucei infected intact and CD1d -/- mice showed these were 
similar (NKp46-, CD49b-, Ly49 C,F,I-, Ly49 H-, FasL+, 80% 2B4+, and CD160lo) as were splenic 
B2 B cells from both strains of infected mice (MHC class Ihi, Fas+, CD48+ and CD60+) suggesting 
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that differences in expression of these receptors and ligands are not responsible for differential 
NK cell degranulation and depletion of B2 B cells. However, while the level of CD1d expression 
was similar on splenic B2 B cells of PLC-/- T. brucei infected and naive intact mice, it was 
strikingly increased on NK cells from the infected intact mice, raising the possibility that negative 
signaling through CD1d by an unknown T. brucei PLC-sensitive ligand prevents degranulation 
and cytotoxic depletion of B2 B cells in these mice.  
 
Introduction 
 
Trypanosoma brucei expresses on its surface about 10 million copies of a single species of 
variable surface glycoprotein (VSG) encoded by a single VSG gene. These VSGs, which form an 
almost contiguous monolayer, assemble as non-covalent homodimers with each VSG attached to 
the plasma membrane by a glycosylphospatidylinositol (GPI) anchor [181]. The VSG coat 
contributes to the survival of the flagellated extracellular protozoan by masking plasma 
membrane components that activate the alternative complement pathway[24]. In addition, GPI 
anchoring of VSGs on the outer lipid leaflet of the plasma membrane allows the homodimers to 
independently rotate and diffuse in the plane of the membrane, and their packing on the 
trypanosome surface results in only a subset of N terminal VSG epitopes being accessible to 
antibodies[182]. As a result of these properties and of trypanosome motility, the complexes of 
VSG and antibody that form on the surface of intact trypanosomes are small and are moved 
directionally [183] by hydrodynamic force [184] into the flagellar pocket, where they are 
endocytosed and the antibody degraded in endosomes [185,186] thus reducing the efficacy of 
antibody mediated trypanosome clearance. Eventually, an adequate concentration of VSG 
specific antibodies is achieved in host plasma to cause trypanosomes to be cleared by 
complement dependent phagocytosis in the liver and other organs [187,188]. However, VSG 
antigenic variants [189] remain and expand the parasitic burden until a new antibody response is 
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generated. This process recurs, resulting in waves of parasitemia, each arising from new variant 
antigenic types.   
Trypanosome infections can eventually resolve through self-cure in trypanosomiasis-resistant 
hosts e.g., African wildlife species[52,190,191], possibly because immune responses of these 
hosts reduce the parasite burden below that required to sustain antigenic variation which has been 
shown to occur at rates of 1.9x10-6 to 6.9x10-3 switches/cell/generation depending on the parasite 
variant antigenic type examined [192]. In contrast, trypanosome infections do not typically 
resolve in trypanosomiasis-susceptible mammals, perhaps as a result of immunosuppression 
which severely compromises IgG antibody responses against VSGs or other trypanosome 
antigens in infected people and livestock [84,85] and which rapidly inhibits trypanosome specific 
IgM and IgG antibody responses in infected mice [75,76]. Mechanisms of T. brucei induced 
immunosuppression of antibody responses are unresolved in people and cattle, but partially 
resolved in mice. 
 
Suppressed humoral immunity in T. brucei infected mice results from infection-induced depletion 
of splenic B cells of the B2 lineage [75] as a result of natural killer (NK) cell mediated 
cytotoxicity [193]. Inactivation of this process through perforin gene deletion results in the 
development of high titer IgM and IgG antibody responses against VSG and many other 
trypanosome antigens, sustained control of trypanosome parasitemia, sustained blood packed cell 
volume and body weight and prolonged survival after infection, all of which are characteristics 
that are shared by infected trypanosomiasis resistant animals. The findings suggest that diverse 
indicators of pathology in infected trypanosomiasis susceptible hosts are linked to 
trypanosomiasis-induced immunosuppression. 
 
Inflammatory macrophages and TNF-producing/iNOS-expressing dendritic cells (tipDC) are 
implicated in mechanisms of T. brucei-induced immunopathology[69,70,71,72,73,74] and studies 
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in animal models show that responses of these cells are induced by trypanosome components, 
particularly the PLC-cleavage fragments of the membrane form of VSG [61,68].  The contention 
that PLC cleavage products play a major role in trypanosomiasis-associated immunopathology is 
supported by findings that removing PLC coding sequence from the T. brucei genome decreases 
parasite virulence in mice infected with pleomorphic T. brucei [22]. It facilitates in the host a 
switch from a pro-inflammatory TH1 to an anti-inflammatory TH2 T cell response during 
infection [57,67], and reduces the degree of immunosuppression and pathology induced by the 
parasites [21] resulting in sustained humoral immune competence and control of parasitemia [21]. 
Thus intact mice infected with PLC-/- T. brucei have a similar absence of immunopathology to 
perforin-/- mice infected with intact T. brucei consistent with the possibility that PLC is required 
to elicit the B cell destructive NK cell response. 
 
PLC indirectly enhances transferrin acquisition by the parasites[194] and has a minor role in 
excision of the VSG coat during parasite differentiation to tsetse fly gut forms[195]. However, 
these functions of the enzyme are not essential for viability or infectivity and it is generally 
agreed that the PLC serves mainly as a virulence factor in mammals.  This suggests that PLC was 
selected through evolution to enhance survival of T. brucei in its mammal hosts. Consequently 
elucidating the PLC-dependent virulence mechanism is a critical step towards developing 
interventions that will negate its effect on the immune system in trypanosomiasis-susceptible 
hosts. Here we address the possibility that T. brucei PLC plays a key role in infection-induced 
deletion of B2 B cells by NK cells. In support of this possibility our findings show that infection 
of intact C57BL/6 mice with PLC-/- T. brucei does not cause the deletion of splenic B cells. 
However, the same parasites delete splenic B 2 cells from CD1d-/- C57BL/6 mice with 
comparable efficacy to that of intact T. brucei.  Additional studies reported here suggest against 
induction of an anti-pathology response by the PLC-/- T. brucei in intact mice and implicate 
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antagonism of NK cell degranulation by negative signaling as the key mechanism in determining 
B2 B cell survival.  
 
 
Results 
 
Infection of C57BL/6 mice with PLC-/- T. brucei does not cause depletion of splenic B2 B 
cells 
In order to assess the role of T. brucei PLC in infection induced loss of splenic B2 B cells we 
compared splenic B cell dynamics in C57BL/6 mice infected with 5000 exponentially growing T. 
brucei AnTat 1.1E [196] and 5000 T. brucei EATRO 1125 which are engineered to lack a 
functional gene encoding PLC (PLC-/-) [197].  T. brucei Antat 1.1E was cloned from EATRO 
1125 after several passages in rats and mice [196]. As shown previously (see chapter 1) C57BL/6 
mice infected with T. brucei Antat 1.1E lose splenic B2 B cells and humoral immune competence 
by 10 days after infection [75] and die between 30 and 40 days post infection with fulminating 
parasitemia [76,182,198]. In contrast C57BL/6 mice infected with PLC-/- T. brucei survived for 
100 -125 days post infection (Fig. 1A) and numbers of splenic transitional type 1, 2 and 3 B cells, 
marginal zone B cells, and follicular B cells were not reduced during infection with the PLC-/- 
parasite at 10 dpi (Fig. 1B-F), and for at least 90 dpi (data not shown).  Thus T. brucei PLC is 
required for infection-induced depletion of splenic B2B cells in intact C57BL/6 mice. 
 
In the absence of host CD1d, virulence is restored to the PLC-/- T. brucei 
CD1d is a MHC1 like molecule that has been shown to present glycolipid antigen, including T. 
brucei VSG-GPI, to the T cell receptors of NKT cells [199].  Administration of GPI to mice prior 
to infection with T. brucei provides a degree of protection against infection-induced pathology 
[200] and is host CD1d-dependent[201], raising the possibility that loading of CD1d by VSG-GPI 
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in mice infected with PLC-/- T. brucei might stimulate an anti-pathology response. In order to 
discern whether CD1d plays a role in preventing depletion of splenic B2 B cells by PLC-/- T. 
brucei, CD1d-/- C57BL/6 mice were infected with the PLC-/- parasites or with T. brucei Antat 
1.1E.  Results presented in Fig 2 show that infection of the CD1d-/- mice with either intact or 
PLC-/- T. brucei caused depletion of splenic B2 B cells. In addition, the infected CD1d-/- mice 
developed anemia evidenced by a decrease in blood packed cell volume similar to that observed 
in mice infected with intact T. brucei(Fig3) and died between 30 and 40 dpi  irrespective of 
infection with intact or PLC-/- T. brucei (data not shown).  Thus low virulence of PLC-/- T. brucei 
requires host CD1d expression.  
 
Neither T cells nor Natural killer T cells are required for low virulence of PLC-/- T. brucei  
To determine whether NKT cells or other T cells play a role in maintaining the low virulence of 
PLC-/- T. brucei in intact C57BL/6 mice, C57BL/6 mice lacking the genes for both the beta and 
delta chains of the T cell receptor and hence lacking all T cells and NKT cells (TCR-/- C57BL/6) 
were infected. Splenic B2 B cells were not depleted from the spleens of the PLC-/- T. brucei 
infected TCR-/- mice by 10 dpi (Fig4 A - E) or at later stages of infection  and the infected mice 
survived for > 60 dpi (data not shown) at which time the study was terminated. These data show 
that neither NKT nor other T cells are required to maintain the low virulence of PLC-/- T. brucei.  
  
Co-infection with PLC-/- T. brucei does not reduce the virulence of T. brucei AnTat 1.1E in 
C57BL/6 mice 
Despite the lack of requirement for NKT and other T cells in suppressing the virulence of PLC-/- 
T. brucei in intact C57BL/6 mice, it remains possible that PLC-/- parasites stimulate a CD1d-
dependent anti-pathology response.  In order to assess this possibility intact mice were infected 
with PLC-/- T. brucei at the same time as, or 15 days prior to, infection with T. brucei AnTat 1.1E.  
At day 10 post infection with T. brucei Antat 1.1E, spleen cells were harvested and analyzed for 
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the portion and numbers of B2 B cells. Transitional, marginal zone and follicular B cells were 
significantly reduced in the co-infected mice as compared to that in naïve mice (day -15 co-
infection data shown in Fig 5) and the levels of depletion were similar to that obtained in 
C57BL/6 mice infected with T. brucei AnTat 1.1E alone (see Fig 1).  Furthermore, co-infected 
mice died within 30 to 40 days after infection with T. brucei AnTat 1.1E (data not shown) 
showing that the co-infection with PLC-/- parasites did not reduce the virulence of T. brucei 
Antat1.1E in C57BL/6 mice.   
  
Depletion of NK1.1+ cells prevents loss of splenic B2 B cells during PLC-/- infection of CD1d-
/-
 mice 
T. brucei AnTat1.1E infection-induced B cell depletion is dependent upon the presence of NK 
cells and is abrogated through depletion of these cells during infection.  To assess whether NK 
cells are also required for depletion of B2 B cells during PLC-/- T. brucei infection of CD1d-/- 
mice, NK1.1+ cells were depleted from the mice by administration of anti-NK1.1 mAb on days -
1, 3, and 7 after infection. Control infected Cd1d-/- mice were administered an irrelevant IgG2a 
mAb as an isotype control. Splenic B2 B cells were depleted from infected CD1d-/- mice 
administered the irrelevant mAb and retained in mice treated with anti-NK1.1 mAb (Fig 6). Thus 
PLC-/- T. brucei infection induced depletion of B2 B cell from the spleens of CD1d-/- mice 
requires NK1.1+ cells similar to the depletion of B2 B cells from the spleens of intact mice by T. 
brucei AnTat 1.1E.  
CD1d-dependent suppression of NK cell degranulation in mice infected with PLC-/- T. 
brucei  
During infection of intact mice with intact T. brucei, NK cells acquire a novel activation 
phenotype expressing characteristics of both immature NK cells (NK1.1+, CD3-, NKp46-, CD49b-
) and activated degranulated mature NK cells (FasL+, TRAIL+, CD1dhi, CD107a+). During 
infection of C57BL/6 mice with PLC-/- T. brucei the NK cells also acquire a novel activation 
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phenotype as shown in Fig 7. The NK cells in C57BL/6 mice infected with PLC-/- T. brucei do 
not express NKp46 distinguishing them from almost all NK cells in uninfected C57BL/6 mice 
(Fig 7A).  They also express the death receptor ligand FasL, the MHCI like molecule C1d as well 
as low levels of TRAIL as do the NK cells in mice infected with T. brucei AnTat 1.1E (Fig 7B-D) 
and a high portion of the cells lose expression of CD49b although not as high as that seen in mice 
infected with T. brucei AnTat1.1E (Fig 7E).  Unstimulated mature NK cells in uninfected 
C57BL/6 mice express NKp46 and CD49b (Fig 7A, E) but not FasL (Fig 7B). Importantly, most 
of the NK1.1+ CD3- cells (NK cells) in intact C57BL/6 mice infected with PLC-/- T. brucei do not 
acquire surface expression of CD107a, which distinguishes them from NK cells in C57BL/6 mice 
infected with T. brucei AnTaT 1.1E (Fig 7F).  CD107a, also called LAMP1, is a cytotoxic 
granule marker and appears on the surface membrane of NK cells only upon degranulation.  It is 
therefore a functional marker for cell mediated cytotoxicity, and its absence from the surface of 
splenic NK cells from PLC-/- T. brucei infected C57BL/6 mice is consistent with lack of splenic 
B2 B cell depletion from these mice.   
 
Several differences were observed in NK cells of naïve and PLC-/- T. brucei infected CD1d-/- 
C57BL/6 mice compared to naïve and similarly infected C57BL/6 mice. Firstly, most NK cells in 
naïve CD1d-/- mice lack the NKp46 activating receptor (Fig 8A). Secondly, almost all NK cells in 
CD1d-/- mice that are infected with PLC-/- T. brucei lose expression of CD49b (Fig 8B), acquire 
expression of FasL (Fig 8C) and have strong surface expression of CD107a (Fig 8D) thus 
recapitulating the phenotype of B cell destructive NK cells in intact mice infected with T. brucei 
AnTat 1.1E. MHCI is upregulated on B2 B cells during PLC-/- infection of both intact and CD1d-/- 
mice (Fig 9A).  Whereas the expression of the cognate inhibitory and activating receptors for 
MHCI, Ly49C, F, I (inhibitory) and H (activating), are downregulated on NK cells during 
infection of both CD1d-/- (Fig 9A-C) and intact (Fig 9D-F) C57BL/6 mice with either intact or 
PLC-/- T. brucei.   
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Surface expression of CD160, the natural killer cell receptor for CD1d, remains unchanged 
during infection of intact or CD1d-/- mice with either intact or PLC-/- T. brucei  (representative 
data from intact C57BL//6 shown in Fig 10A)as does expression of CD1d on B cells in the intact 
mice (see Fig 8).  The molecule CD244 (2B4) is expressed on NK cells and is thought to be an 
inhibitory receptor for NK cells while it is thought to act as a stimulatory ligand to lymphocytes 
that express CD48 [202].  2B4 expression on NK cells is unchanged during intact or PLC-/- T. 
brucei infection of C57BL/6 mice (Fig 10B), except in the absence of host CD1d, in which case 
2B4 expression is upregulated (Fig 10)and CD48 expression on B cells remains unchanged 
during intact or PLC-/- infection of either intact or CD1d-/- mice (representative data from 
C57BL/6 shown in Fig 10D). 
 
Intravenous administration of T. brucei Antat 1.1E lysate to C57BL/6 mice infected with 
PLC-/- T. brucei does not cause depletion of splenic B2 B cells or increase virulence   
PLC cleaves the GPI anchor of GPI-VSG resulting in the release of water soluble 
glycosylinositolphosphate-VSG dimers (sVSG) and retention of T. brucei membrane bound 
dimyristyl glycerol.  Both the dimyristyl glycerol and phosphoglycan moieties of VSG-GPI 
stimulate macrophages. In combination they induce production of TNFα [203] and the 
phosphoglycan moiety alone stimulates INFγ activated macrophages to produce TNFα [203]. 
Since sVSG cannot be generated by PLC-/-T. brucei it is possible that this parasite component, or 
its phosphoglycan moiety, alone or in combination with T. brucei membrane associated 
dimysteryl glycerol, causes the infection-induced depletion of splenic B2 B cells. To determine 
whether sVSG in combination with T. brucei membrane fragments contributes to splenic B2 B 
cell depletion, mice were infected with PLC-/- T. brucei or sham infected and repeatedly 
administered intravenous injections of 108 freeze-thaw lysed T. brucei AnTat 1.1E prepared in the 
presence of DNAase and protease inhibitors. The extracts contain sVSG and little or no 
87 
 
membrane form VSG determined by SDS-PAGE in 7% gels (data not shown). The parasite 
lysates were injected on days 6, 7, and 8 post infection which coincides with clearance of peak 
parasitemia in the PLC-/- T. brucei infected mice (see Fig 1A), or to uninfected animals, and 
splenic B2 B cell numbers were determined 2 days after the last injection.  Administration of T. 
brucei AnTat 1.1E freeze thaw lysate did not cause depletion of splenic B2 B cells from either the 
uninfected mice, or from mice infected with the PLC-/- parasites (Fig. 11). Thus, T. brucei 
membrane fragments and sVSG in the lysate do not elicit B cell destructive NK cells in naïve 
mice, and in mice infected with the PLC-/- T. brucei, at least when administered by the 
intravenous route at the concentrations used.  
 
 
Discussion 
The studies reported above show that PLC-/- T. brucei are relatively avirulent in intact C576BL/6 
mice, but of similar virulence to intact T. brucei in CD1d-/- C57BL/6 mice. This difference in 
virulence is at least in part a result of differential depletion of splenic B2 B cells in the two strains 
of infected mice. Thus intact C57BL/6 mice chronically infected with PLC-/- T. brucei maintain 
splenic B2 B cells at pre-infection levels, do not experience a decline in blood packed cell volume 
and survive for 125 dpi. Whereas CD1d-/- C57BL/6 mice that are infected with the same parasites, 
and intact mice infected with intact T. brucei, rapidly lose splenic B2 B cells, have a severe 
decline in blood packed cell volume and die by 35 dpi. These findings both clarify and 
complicate our understanding of how T. brucei PLC functions as a virulence factor. 
 
T. brucei VSG specific PLC is capable of cleaving VSG-GPI resulting in the release of water 
soluble VSG (sVSG) bearing C terminal residual glycosylinositolphosphate (GIP) and leaving 
dimyristyl glycerol attached to the outer leaflet of the trypanosome plasma membrane. This 
occurs in parasites with ruptured membranes, but does not occur in healthy trypanosomes 
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[204,205]. The VSG-GPI substituents activate cells of the innate immune system and regulate 
macrophage and dendritic cell cytokine expression profiles and antigen presenting function by 
interaction with Type A scavenger receptors on the macrophage and dendritic cell membrane 
[206]. This stimulates an initial pro-inflammatory activation profile [203,207,208]. Target cell 
responses are modified by prior or subsequent interactions of IFNγ receptors with IFNγ, and 
pathogen pattern recognition receptors with CpG and other materials released by dead or dying 
trypanosomes [206,209,210]. The timing of these complex interactions may regulate the balance 
of TH1 and Th2 T cell responses by controlling the magnitude of response and functional 
commitment of the antigen presenting cells, and in so doing affect trypanosome virulence [208]. 
In this regard, control of infection is optimized by an initial Th1 T cell response, which promotes 
production of trypanocidal reactive oxygen and nitrogen intermediates by tissue macrophages, 
and which is subsequently balanced by an anti-inflammatory Th2 T cell response, which prevents 
lethal systemic inflammation. While these observations are consistent with the possibility that 
virulence of T. brucei is linked to production of GIP-sVSG and uncontrolled inflammation at high 
parasitemia, the studies reported here show that release of GIP-sVSG by PLC is not a requirement 
for infection-induced immunopathology and high parasite virulence in CD1d-/- mice thus 
indicating a GIP-sVSG independent virulence mechanism. 
  
Our earlier studies show that high trypanosome virulence in chronically infected mice manifests 
as a rapid depletion of splenic B2 B cells [75], loss of humoral immune competence as well as an 
infection induced decline in blood packed cell volume and early death all of which are linked to 
infection-induced NK cell mediated cytotoxicity. NK cell mediated cytotoxicity is also likely to 
play a central role in the high virulence of PLC-/- T. brucei in CD1d-/- mice because antibody-
mediated depletion of NK1.1 cells, from the infected mice resulted in maintenance of splenic B2 
B cells. The similar nature of pathology arising in T. brucei infected C57BL/6 mice and PLC-/- T. 
brucei infected CD1d-/- mice, namely depletion of B2 B cells and decrease in blood packed cell 
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volume, as well as the requirement for a NK1.1+ cell strongly suggest that the same effector 
mechanism operates in both infection models. 
 
How might the presence of CD1d prevent the induction or effector function of the NK cells?  One 
possibility is that the PLC-/- T. brucei stimulate an anti-pathology response in intact mice but not 
in CD1d-/- mice, however, two lines of evidence suggest against this explanation. First, despite 
studies showing that B cell help is provided by NKT cells that are stimulated by VSG-GPI loaded 
on CD1d[118,199] ( ), NKT cells, indeed all T cells, appear to play no role in limiting virulence 
of PLC-/- T. brucei determined by infection of TCR-/- mice. Splenic B2 B cells were not depleted 
from intact or TCR-/- mice infected with the PLC-/- parasites and survival times of both strains of 
mice were similar and in excess of 100 dpi. Second, intact C57BL/6 mice that were infected with 
PLC-/- T. brucei EATRO 1125 up to 15 days before superinfection with T. brucei AnTat 1.1E, 
showed no protection against the latter parasites which were derived from the parent T. brucei 
EATRO 1125 isolate. Depletion of splenic B2 B cells from the co-infected mice occurred with 
the same kinetics to singly infected mice and both groups of mice died by 35 dpi.  
 
It is also possible that NK cells acquire cytotoxic function in CD1d-/- but not intact mice infected 
with PLC-/- T. brucei. This possibility was investigated by comparative analysis of cell surface 
differentiation antigens expressed on the NK cells in both infection models. There was a good 
deal of similarity in the surface differentiation antigen profiles of NK cells from intact and CD1d-
/-
 C57BL/6 mice infected with the PLC-/- T. brucei, and two striking differences. In both cases 
most of the NK cells in the infected mice were CD3-, NK1.1+. NKp46-, CD49b-, FASL+, TRAIL+, 
Ly49 C,F,I,H-, and 2B4+, thus differing from typical mature NK cells in uninfected mice which 
express NKp46, CD49b, and Ly49C,F,I, in addition to NK1.1 and do not express FasL. These 
infection-induced changes in NK cell differentiation antigen expression are similar to those 
arising on NK cells in intact mice infected with intact T. brucei . Two possibly important 
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distinctions were observed between the NK cells of intact and CD1d-/- mice before and after 
infection with PLC-/- T. brucei. First, splenic NK cells in naïve CD1d-/- mice did not express 
NKp46 unlike those in intact C57BL/6 mice suggesting that CD1d might play a role in normal 
NK cell development and sub-population commitment. To our knowledge this has not been 
reported previously. Second, NK cells in CD1d-/- mice infected with PLC-/- trypanosomes 
acquired strong expression of CD107a, which is expressed on cytotoxic granules and placed on 
the plasma membrane during NK cell degranulation, whereas intact mice infected with the PLC-/- 
trypanosomes did not acquire expression of CD107a. Thus, infection activated NK cells in intact 
C57BL/6 mice infected with PLC-/- T. brucei are not induced to degranulate consistent with 
retention of the putative target B2 B cells in the spleens of infected mice, whereas those in 
infected CD1d-/- mice are induced to degranulate consistent with splenic B cell depletion in these 
mice.  Finally, NK cells in infected C57BL/6 mice have upregulated expression of CD1d on their 
cell surface, which is not possible in CD1d-/- mice.  
 
NK cell killing is regulated by a balance of receptor and ligand interactions that are either 
activating or inhibitory to the NK cell.  The NK cells are known to kill target cells that have 
decreased MHC I on their plasma membrane, designated “missing self” [211].  However, in the 
case of the T. brucei-infected mice, MHCI expression is actually increased on IgM+ cells and, as 
shown here, is increased to a similar extent on IgM+ cells in both intact and CD1d-/- mice infected 
with PLC-/- T. brucei. These findings show that “missing self”, at least in the context of class I 
MHC molecules, is not involved in making the B cells of the infected CD1d-/- mice into targets 
for NK cell. This conclusion is supported by analysis of Ly49 receptor family expression on NK 
cells of the infected mice.  Ly49 family members are Type II C-type lectin-like NK cell receptors 
that bind MHC class I, delivering an activating signal in the case of Ly49H and Ly49D and 
inhibitory signals in the case of other Ly49 receptors that are expressed by the C57BL/6 NK cells, 
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namely Ly49A,C/I,F,G [212]. The Ly49 receptor profiles of NK cells show a decreased 
expression of both inhibitory Ly19C, F, I and activating Ly49H.   
 
Mouse NK cells express an Ig-like receptor CD160 that recognizes both classical and non-
classical MHC class I molecules, the later including CD1d [213]. Importantly, CD1d1 signaling 
to IL-2 activated CD1d1-binding mouse NK cells has been shown to negatively regulate their 
cytotoxic activity [214,215], raising the possibility that signaling though CD160 might also down 
regulate the cytotoxic activity of NK cells in intact mice infected with PLC-/- T. brucei accounting 
for low parasite virulence. Furthermore,  the absence of CD1d-dependent CD160 signaling in NK 
cells of CD1d-/- mice might account for high NK cytotoxic activity and high virulence of PLC-/- 
parasites in this strain.  However, this attractive hypothesis is unlikely to be valid because of the 
unchanged expression of CD1d on B cells and unchanged expression of CD160 on NK cells 
during infections.   
 
Increased expression of surface CD1d on NK cells occurs during infection of intact mice with 
both PLC-/- T. brucei and intact T. brucei raising the possibility that NK cell degranulation on B2 
B cells is inhibited by negative signaling through NK expressed CD1d which is somehow 
circumvented by T. brucei PLC. Direct CD1d signaling has not been reported for NK cells and, 
disappointingly, the absence of PLC in infecting T. brucei could not be compensated by repeated 
intravenous injection of freeze thaw lysed intact T. brucei containing membrane associated PLC, 
as well as GPI substituents generated by PLC. Nevertheless we consider that testing this 
hypothesis is a reasonable next step in resolving how host CD1d and T. brucei PLC jointly 
control depletion of B2 B cells in infected mice, and thus the efficacy of trypanosome specific 
antibody responses. In addition, discovery based approaches including gene expression, plasma 
membrane proteome and cell phosphoproteome analyses of NK and B2 B cells from intact and 
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CD1d-/- mice before, and after, infection with intact and PLC-/- T. brucei, might provide insights 
into signaling pathways that regulate cytotoxic granule degranulation and B2 B cell depletion. 
 
 
Materials and Methods 
Ethics Statement: The study was carried out in strict accordance with the recommendations in the 
Guide for the Care and Use of Laboratory Animals of the National Institutes of Health and 
Guidelines for the Use of Laboratory Animals in Research, Teaching and Testing of the 
International Council for Laboratory Animal Science. All animal studies were approved by the 
Institutional Animal Care and Use Committee, University of Massachusetts, Amherst, MA01003 
USA, as documented in protocol #s 2010-0028, 2013-0049 and 2013-0050. 
Mice and Trypanosomes: Male C57BL/6 (Taconic, Germantown, NY), C57BL/6-prf1tm1sdz/1 
(perforin-/-), , B6.129P2-Fcgr3tm1Sjv/J (CD16-/-), B6(C)-Cd1d1tm1.2Aben/J (CD1d-/-)(Jackson 
Laboratory, Bar Harbor, ME) add MyD88-/- and TRIF-/- (generously provided by Katherine 
Fitzgerald, University of Massachusetts Medical School), (7-9 week old) were infected by 
intraperitoneal (i.p.) injection of 5000 exponentially growing pleomorphic Trypanosoma brucei 
Antat 1.1E or PLC-/-(both derived from EATRO 1125 stock, described in[148]) in blood collected 
from immunocompromised C57BL/6 donors (600r from a 127 Cesium source, 24 hours prior to 
i.p. injection of cryopreserved parasites) and diluted in Dulbecco’s Phosphate Buffered Saline 
(DPBS; GIBCO,Life Technologies), or uninfected by i.p. injection of DPBS.  Parasitemia was 
assessed in blood collected from the tail vein during infection by dilution (1:100) in DPBS and 
counting using a hemocytometer. All mice were housed under barrier conditions.  
Cell isolation and flow cytometric analysis: Spleens were dissected from mice that were killed by 
lethal CO2 inhalation and mechanically dissociated in cold FACS Buffer (1.0% fetal bovine 
serum, FBS, [Atlanta Biologicals] in DPBS). Supernatant was collected, cell pellets prepared by 
centrifugation (500 g, 10 min, 4oC) and red blood cells were lysed by re-suspending each spleen 
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cell pellet in 10ml of cold ammonium chloride lysis buffer (ACK; 0.15M NH4Cl, 1.0 mM 
KHCO3, 0.1mM Na2-EDTA). Incubations in ACK buffer were for 4 minutes on ice after which 
cells were pelleted as above, washed twice in FACs buffer, re-suspended in FACs buffer and 100 
µl aliquots containing 106 cells were added to the wells of a V bottom plate and stained with 
combinations of specific monoclonal antibodies against B cell, T cell and NK cell differentiation 
antigens (listed in Fig S1) to identify these leukocyte populations and subpopulations by 
multicolor flow cytometry as described [75] . Briefly, cells were incubated with a 1:1000 final 
concentration Fc block (CD16/CD32 Fc III/II, eBioscience, San Diego, CA) for 20 minutes at 
4°C, pelleted, resuspended with biotin- or fluorochrome-conjugated primary antibodies (listed 
below) for 30 minutes at 4°C, washed twice in cold FACs buffer, resuspended in 100 µl buffer 
with or without streptavidin (SA) conjugated fluorochromes, which detects cell bound 
biotinylated antibodies, and incubated for an additional 30 minutes at 4°C.  Samples were washed 
twice and resuspended in 300 µl FACs buffer with 1 µg of 7-amino-actinomycin D (7AAD), a 
fluorescent DNA dye that binds to membrane permeable (dead or dying) cells, (EMD Chemicals, 
San Diego, CA).  Analyses were performed using a flow cytometer (LSRII BD Biosciences, San 
Jose, CA) and data processed using FLOWJO software (Tree Star Inc., Ashland, OR) to 
determine the percentages of 7AAD-ve and where stated also 7AAD+ve cells in fluorochrome-
tagged subsets. The total number of cells in each population was determined by multiplying the 
percentages of subsets within a series of marker negative or positive gates by the total cell 
number determined for each tissue. Differences among multiple groups were analyzed by 
ANOVA and means were compared using Tukey’s HSD test when p≤0.05 (GraphPad Prism 
v.4.0, GraphPad Software Inc. San Diego, CA). 
Preparation of T. brucei lysate: Parasite lysate was prepared by suspending 108 DEAE52 purified 
[149] washed T. brucei AnTat 1.1E in 5 ml lysis buffer (DPBS, containing 0.4%NP40 and 
protease inhibitor cocktail [Complete mini tablets, Roche, Indianapolis, IN]). Insoluble material 
was removed by centrifugation at 1000g for 5 mins. 
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Antibodies and detection reagents:  Avidin-APC-Cy7 (San Diego), anti-CD1d-biotin (clone 1B1), 
anti-CD48-boitin (clone HM4810, anti-CD244-APC (clone eBio244f4), anti-CD160-PE (clone 
eBioCNX46-3), anti-DR5-biotin (clone MD5-1), anti-FasL-PE (clone MFL3), anti-Fas-PE-Cy7 
(clone 15A7), anti-H2kb-PE (clone eBM2a), anti-Ly49C/I/F/H-FitC (clone 14B11), anti-Ly49H-
biotin (clone 3D10), anti-NKp46-PE (clone 29A1.4), anti-IgM-PE (clone II/41), anti-NK1.1-APC 
(clone pk136), anti-TRAIL-biotin (clone N2B2), anti-CD23-APC-Cy7 (clone B3B4), anti-CD23-
FITC (clone B3B4), anti-CD45R (B220)-FITC (clone RA3-6B2), anti-CD93–APC (clone 
AA4.1),  anti-CD107a (clone 1D4B) purchased from eBioscience (San Diego, CA);  anti-CD21-
APC (clone 7G6), anti-CD49b FITC (clone DX5) purchased from BD Biosciences (San Diego, 
CA); 7-amino-actinomycin D (7AAD) purchased from EMD Chemicals (San Diego, CA). IFA - 
Anti-MOMA-1(biotin) AbCam (Cambridge MA); Avidin-FITC, BD Pharmingen (San Diego, 
Ca); anti-human/mouse CD45 (B220) eBiosciences (SanDiego, Ca).   
 
NK cell depletion [177,178] and FasL Blocking: Mice were injected intraperitoneally with 500 ug 
anti-NK1.1  IgG2a monoclonal antibody purified from hybridoma (PK136, ATCC Manassas, 
Virginia) culture supernatant by Protein G chromatography, or with an irrelevant control IgG2a 
antibody (M9144, Sigma-Aldrich). Treatments were repeated on days 4 and 7 after the first 
injection of anti-NK1.1 and depletion of splenic NK1.1+ cells was assessed on days 3, 7 and 10 
using flow cytometry as described above. Blocking of Fas-FasL signaling was performed as 
previously described[179]; anti-FasL MFL4 antibody (Ab) [180] was injected intraperitoneally 
(500 µg per mouse).  
Statistics: Results comparing data obtained from infected animals and from non-infected controls 
were subjected to two-tailed T tests with significant differences reported as follows: p≤0.05, (**) 
p≤0.01, (***) p≤0.001.  Differences among multiple groups were analyzed using ANOVA and 
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means were compared using Tukey’s honest significant difference (HSD) test when p≤0.05 
(GraphPad Prism v.4.0, GraphPad Software Inc. San Diego, CA). 
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Figure 3 CD1d-/- mice develop anemia during PLC-/- infection Packed (red blood)  r standard deviation, 
of 3 mice per group.  Significance (*<0.05, **<0.001, ***<0.0001) is determined using one way ANOVA 
and Tukey’s HSD test comparing uninfected (naïve) controls to infected individuals 
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CHAPTER V 
CONCLUDING COMMENTS 
 
 
Studies from the Magez and Black laboratories, on which I was a co-author (see appendix), had 
shown that T. brucei infection induced immunosuppression in the C57BL/6 model of Animal 
African Trypanosomiasis results from the depletion of developing and mature B2 B cells. My 
studies were aimed at elucidating the mechanism of B2 B cell depletion, and in the process of 
answering this question I showed that splenic CD8+ T cells were also depleted (chapter 2). To 
gain insights into possible effector mechanisms I first performed T. brucei infections in strains of 
C57BL/6 mice lacking genes encoding components of apoptotic cell death pathways (TNF 
receptor), cytotoxic cell effector molecules (C3, perforin), receptor molecules (TCR, MyD88, 
TRIF) and antigen presenting molecules (CD1d, beta-2 microglobulin).  It was hoped that one or 
other gene deletion would prevent infection-induced deletion of the B cells, although it was 
realized that redundant pathways might preclude this.  
In fact, as shown in Chapter 1 of this thesis, only one of the knock out models used gave an 
indication of the mechanism responsible for cell depletion in the infected mice.  I discovered that 
perforin gene expression is required for depletion of both splenic B2 B cells as well as splenic 
CD8+ T cells (chapter 2).  Infection of TCR deficient mice and CD1d deficient mice ruled out an 
essential role for T cells and natural killer T cells in B2 B cell depletion.  Finally, treatment with 
monoclonal antibody that kills NK cells as well as NKT cells revealed that infection induced 
deletion of B2 B cells in C57BL/6 mice requires these cells. Thus, NK cell mediated cytotoxicity 
is most likely responsible for splenic B and CD8 T cell depletion in the T. brucei infected mice. 
This proved to have substantial biological consequence, because mice that were unable to mount 
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cell mediated cytotoxic responses, i.e., in perforin-/- mice, had a superior capacity to control 
infection with T. brucei. They survived for at least twice as long as similarly infected intact mice, 
retained splenic B2 B cells and CD8 T cells, generated high titer IgG1 and IgG2a antibody 
responses against trypanosome antigens, which infected intact mice were unable to do, and 
control parasitemia effectively up to the time studies were terminated because the infected mice 
developed gut hemorrhages of unknown etiology.  
My studies also showed that natural killer cells in T. brucei infected mice take on a novel 
phenotype which shares qualities with both activated natural killer cells and with immature 
natural killer cells.  The activating receptor NKp46 and the cell adhesion molecule CD49b 
(integrin alpha 2 subunit) are both markers of mature natural killer cells; both are lacking on 
natural killer cells by day 10 post infection with T. brucei when  B2 B cells and CD8+ T cells are 
deleted.  Yet Fas ligand is upregulated suggesting an activated state.  The non-classical MHC 
protein CD1d is also upregulated on natural killer cells during infection while it remains 
unchanged on both B and T cells, while 2B4, the receptor for the B cell blast antigen CD48 is 
similarly expressed on naïve and activated NK cells and there is little change in expression of its 
ligand on naïve and infection activated B cells.  Importantly, these natural killer cells are acting 
effector cells as indicated by the presence of the cytotoxic granule marker CD107a on their 
surface membrane. 
Using parasites which lack the only known Trypanosome virulence factor, GPI-PLC, I observed 
in Chapter 3 that infection induced loss of splenic B2 B cells and CD8+ T cells in C57BL/6 mice 
requires expression by the T. brucei of VSG-GPI specific PLC (GPI-PLC).  Paradoxically, I also 
observed that GPI-PLC-/- T. brucei were highly virulent in CD1d-/- C57BL/6 mice, indicating that 
virulence of T. brucei is not determined by GPI-PLC alone, but is also regulated by host CD1d.  
Interestingly, during infection of intact C57BL/6 mice with GPI-PLC-/- T. brucei, i.e., a 
combination in which the infection is relatively avirulent, NK cells were found to acquire most 
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but not all of the infection-induced phenotypic markers seen in mice infected with virulent intact 
T. brucei. In both cases the NK cells lacked expression of NKp46 and CD49b, and expressed high 
levels of FasL and CD1d.  However, whereas NK cells in mice infected with intact T. brucei has 
a high level of surface CD107a indicative of cytotoxic granule degranulation, the NK cells in 
intact mice infected with GPI-PLC-/- T. brucei did not have surface CD107a and thus had not 
degranulated-/-.   
What is activating NK cells to degranulate and kill splenic B2 B cells and CD8+ cells during 
infection with intact T. brucei but not during infection with GPI-PLC-/- T. brucei?  GPI-PLC 
removes the lipid moiety of the T. brucei VSG-GPI anchor by hydrolyzing the phosphodiester 
bond of phosphatidylinositol to form a free 1, 2-diacylglycerol and glycopeptide-bound inositol 
cyclic-1, 2-phosphate.  In the absence of GPI-PLC trypanosomes are unable to cleave the GPI-
anchored VSG. This presumably leaves the intact GPI available for processing by cells that 
phagocytose antibody and complement coated trypanosomes and ultimately presentation of the 
glycan-lipid moiety of GPI on the MHC class 1 like molecule CD1d.  Because GPI-PLC-/- T. 
brucei are avirulent in intact C57BL/6 mice but virulent in CD1d-/- C57BL/6 mice it is reasonable 
to hypothesize that CD1d-loaded with the lipoglycan from VSG-GPI provides a negative signal to 
responding NK cells preventing these cells from degranulation.  If so, infection induced NK cells 
would be expected to express CD160 which is the receptor for CD1d, while B2 B cells and CD8+ 
T cells in the infected mice would be expected to express CD1d and to take up and process VSG-
GPI. While these predictions were not exhaustively studied, initial studies make it rather unlikely 
that the hypothesis is correct. 
I found that expression of CD1d on B2 B cells and CD8 T cells did not change in C57BL/6 mice 
infected with intact T. brucei. Rather, it is the NK cells that upregulate CD1d expression during 
infection and this occurs whether the mice are infected with intact or GPI-PLC-/- T. brucei.  In 
addition, expression of CD160, which is the receptor for CD1d did not increase on the NK cells 
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of infected mice.  How then could CD1d on NK cells negatively regulate their degranulation in 
mice infected with GPI-PLC-/- T. brucei, while having little or no effect on their degranulation in 
mice infected with intact T. brucei?  Given that NKT cells respond to lipoglycan presented on 
CD1d, it could be argued that these cells somehow contribute to regulating NK cell 
degranulation. However, because intact T. brucei and GPI-PLC-/- T. brucei retain their virulence 
profiles in intact mice and mice lacking all T cells, this possibility is excluded.  This line of 
reasoning leads me to propose that CD1d on the T. brucei infection induced NK cells serves 
directly as a signaling molecule that regulates degranulation and is inhibited by VSG-GPI. How 
this would work is unclear at this time.  However, there is precedent that CD1d can serve as a 
signaling molecule, at least on intestinal epithelial cells where cross-linking of CD1d causes the 
production of the anti-inflammatory cytokine, Il-10, which is protective against inflammatory 
bowel disease. [216,217].  
In Chapter 2 we show that toll like receptors potentially play an important role in the deletion of 
CD8+ T cells by NK cells in mice infected with intact T. brucei (though not so in the case of B2 B 
cell deletion).  I found that T. brucei infected MyD88-/- and TRIF-/- mice do not have diminished 
splenic CD8+ T cell numbers.  However, both uninfected MyD88-/- and TRIF-/- mice had very low 
splenic T cell numbers (less than half the numbers of total T cells, about a fifth the number of 
CD4+, and less than half the numbers of CD8+) which increased during infection nearly to 
numbers seen in uninfected intact C57BL/6 mice.  The low numbers of T cells in resting MyD88-
/- and TRIF-/- mice is problematic when trying to draw conclusions on the data showing an 
increased number of CD8+ T cells during infection of these animals, but the fact that CD8+ cells 
are able to proliferate without deletion by natural killer cells does suggest a role for toll like 
receptors in T. brucei induced CD8+ cell depletion.  The role of MyD88 during infection is 
complex; while on the one hand MyD88 plays an important role in controlling T. brucei 
parasitemia[218], on the other hand MyD88 has been shown to facilitate T cell and T. brucei 
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infiltration across the blood brain barrier[218] and progression to meningoencephalitic stage of 
infection, thus contributing to virulence. It is unclear whether MyD88 regulates expression of an 
NK ligand on CD8+ T cells or a receptor for a CD8+ T cell ligand on the NK cells.  
To summarize, we have shown that B2 B cell deletion during infection of C57BL/6 mice requires 
and most likely is mediated by a novel population of natural killer cells through a perforin 
dependent mechanism as is depletion of CD8 T cells.  NK cell dependent killing of B2 B cells 
and CD8 T cells during T. brucei infection is dependent on factors both within the host as well as 
the parasite.  Trypanosome GPI-PLC plays a critical role in parasite virulence, host ability to 
control parasitemia, survival and in the induction of natural killer cells which target splenic B2 B 
cells and CD8 T cells during infection.  The presence of host CD1d molecule is also critical for 
low virulence phenotype of infection with PLC deficient parasites.  In addition, MyD88 
expression by the host is necessary for infection induced depletion of CD8 T cells but not B2 B 
cells. Thus, in answering the question of how B2 B cells are depleted in T. brucei infected mice, I 
have opened many new questions, notably: (i) how are the novel NK cells induced, (ii) do they, as 
seems likely from my studies, directly kill B2 B cells and CD8 T cells, (iii) if so what receptor 
and ligand interactions are involved and what are the roles of T. brucei GPI-PLC and host CD1d 
in regulating NK cell cytotoxic activity and (iv) is this apparently novel method of 
immunosuppression restricted to infected mice or a feature of acute trypanosomiasis and other 
diseases in other host species.     
 
Future Directions 
It will be important to know whether natural killer cells which arise during infection originate in 
the spleen or emigrate from elsewhere.  Currently, it is unknown whether resident natural killer 
cells are stimulated by infection to differentiate into the NK1.1+, CD3-, NKp46-, CD49-, CD1d+ 
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natural killer cells we observe, whether these cells differentiate from a small population of 
progenitors which is resident in the spleen or elsewhere, or whether this population migrates into 
the spleen from another organ such as the liver, lung, intestine or bone marrow.  
Currently studies are underway to determine whether natural killer cells taken from an intact 
mouse will be induced to differentiate into the B2 B cell killing cells (NK1.1+, CD3-, NKp46-, 
CD49-, CD1d+, CD107a+) in perforin knockout mice, and if they will indeed be induced to kill in 
the context of infection within perforin deficient animals.  If the putative (T. brucei induced)  B 
cell (and CD8+ T cell) killer NK cells are resident splenic natural killer cells we would expect 
perforin+ cells to differentiate and B2 B cells (and CD8+ T cells) to be deleted in the T. brucei 
infected perforin-/- animal.    If the donor natural killer cells do not differentiate into the novel 
infection-induced NK cells, this would suggest the possibility that the differentiated cells we see 
during infection are emigrating to the spleen from another tissue or are arising from a resident 
precursor cell. 
Secondly, it will be beneficial to know what signaling pathway(s), are involved in both the 
differentiation and activation to effector function (killing).  Given my data showing that under 
condition of a PLC-/- infection natural killer cells are differentiated into the activated, immature 
phenotype described above, but are not killing, the logical conclusion is that there are two 
mechanisms involved, one mechanism which induces natural killer cell differentiation, and a 
second which is the trigger for cytotoxic effector function.  We have preliminary data which 
suggest that soluble factors in the serum of infected mice are enough to induce the appearance of 
T. brucei induced natural killer cell phenotype but not killing of B cells or CD8+ T cells 
(unpublished results R. Hillard and S. J. Black).  Also, it would be beneficial to these studies to 
show natural killer cell killing through cytotoxic assay as well as visualization of synapse with 
putative target cells. This poses a challenge as it has been established that natural killer cells from 
T. brucei infected mice do not kill yac-1 cells ex vivo and we have preliminary data that they also 
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do not kill resting splenic B2 B cells. Studies are on-going to determine if they kill myeloma B 2 
B cells, LPS activated B cells, and B cells from intact C57BL/6 mice infected with GPI-PLC-/- T. 
brucei. It would be helpful if we can identify a myeloma cell target as this could be genetically 
manipulated to investigate the relevance of expressed genes to killing, which might facilitate 
ligand identification.  
It will also be important to know what receptors are expressed by the novel NK cells that arise in 
T. brucei infected mice.   So far we have approached this question by hypothesis and test, but a 
more discovery-based approach is warranted.  Insights into relevant receptors, i.e., receptors that 
mediate the recognition of B2 B cells and CD8 T cells might be gained by characterization of the 
infection-induced NK cell plasma membrane proteome, and proteins associated with lipid rafts 
which are known to harbor several NK receptors including 2B4. It will also be important to 
identify and compare splenic NK cell plasma membrane antigens and associated proteins that are 
phosphorylated on serine/threonine and tyrosine residues in intact C57BL/6 mice infected with 
intact T. brucei compared to GPI-PLC-/- T. brucei, and in intact mice infected with GPI-PLC-/- T. 
brucei compared to CD1d-/- mice infected with the same parasites. These latter comparisons are 
expected to inform on signaling proteins that regulate cytotoxic granule degranulation.   
It will be important to show presence (or absence) of intact GPI presentation during infection 
with PLC-/- T. brucei infection versus antigen presentation during infection with intact T. brucei.  
It is known that endogenous GPI  is a natural ligand for CD1d[219] and that CD1d is capable of 
binding Trypanosome GPI[220].  We will design experiments to assess GPI and VSG antigen 
presentation during infection.  T. brucei bloodstream form are unique in GPI formation in that 
they use a fatty acid remodeling in which  GPI intermediates are replaced with myristic 
acid(C14).  This can be exploited because trypanosomes grown in the presence of synthetically 
labeled C14 will then have the label intercalated into their GPI.  This would allow us to assess 
whether GPI from PLC-/- T. brucei is processed by NK cells and is then associated with CD1d on 
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NK cells.  To compare presentation of mVSG and sVSG from PLC-/- parasites versus from intact 
T. brucei metabolic labeling of carbohydrate moieties would also be necessary.  
Finally, Trypanosomiasis is socially and economically important as a disease which affects 
humans and cattle.  Infection in human and trypanosusceptible cattle are also characterized by 
profound immune suppression [133,221,222].  Infected Zebu cattle have low antibody titer to 
vaccine antigens, and T. congolense infected cattle have depressed production of antibody[223] 
and 117 human subjects infected with Human African Trypanosomiasis have been described as 
having a lowered antibody titer to vaccine antigen after suffering trypanosomiasis [102], though 
the authors assumed that this reduced titer would still be protective.  It would be important to 
assess whether susceptible cattle suffer the same loss of splenic B2 B cells and CD8+ T cells and 
importantly, whether natural killer cells differentiate (or arise) which have a similar phenotype to 
the natural killer cells in mice and whether natural killer cells play a role in pathology in cattle.   
There is little known about the role of natural killer cells outside of the context of cancer and viral 
infection [224] and up until this point there has been little attention into the role of natural killer 
cells during trypanosome infections[225].  Future studies into the role of natural killer cells in the 
pathogenicity of trypanosomiasis could lead to a better understanding of not only the diseases 
caused by African Trypanosomes, but potential could lead to insights into other protozoan 
infections, and immune regulation.  
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